

20 NOV 1996

D A C

FORM PTO-1390 (REV 10-93)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER
				IMI-040CP3
				U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 08/737904
INTERNATIONAL APPLICATION NO. PCT/US94/09024	INTERNATIONAL FILING DATE 05 August 1994 (05.08.94)	PRIORITY DATE CLAIMED 13 August 1993 (13.08.93)		
TITLE OF INVENTION T CELL EPITOPES OF RYEGRASS POLLEN ALLERGEN				
APPLICANT(S) FOR DO/EO/US Irwin J. GRIFFITH; Mei-Chang KUO; and Mohammad LUQMAN				
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:				
<ol style="list-style-type: none"> <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. <input type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). <input type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). Three (3) DPOAs enclosed (executed). <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 				
Items 11. to 16. below concern document(s) or information included:				
<ol style="list-style-type: none"> <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. <input type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. <input type="checkbox"/> A substitute specification. <input type="checkbox"/> A change of power of attorney and/or address letter. 				
<ol style="list-style-type: none"> <input checked="" type="checkbox"/> Other items or information: Certificate of Express Mailing (1 sheet); Petition under 37 CFR 1.137(b) for Revival of the Above-Identified Unintentionally Abandoned Application (2 sheets); PCT Request (4 sheets); Chapter II Demand (4 sheets); Invitation to Correct Defects in the Demand (2 sheets); Response to Invitation to Correct Defects in the Demand (2 sheets); International Published Application (WO 95/06728) (110 sheets); International Search Report (5 sheets); Written Opinion (5 sheets); Response to First Written Opinion (9 sheets); International Preliminary Examination Report (6 sheets); Sequence Diskette; and postcard receipt. <p>(Also enclosed are checks in the amount of \$2056.00 representing the total National Fee due and \$1290.00 representing the Petition to Revive Fee, based on large entity status - see page two)</p>				

U.S. APPLICATION NO (if known, see 37 CFR 1.5)	INTERNATIONAL APPLICATION NO PCT/US94/09024	ATTORNEY'S DOCKET NUMBER IMI-040CP3																				
		CALCULATIONS PTO USE ONLY																				
<p>17. <input checked="" type="checkbox"/> The following fees are submitted:</p> <p>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):</p> <p>Search Report has been prepared by the EPO or JPO \$910.00 X\$880.00</p> <p>International preliminary examination fee paid to USPTO (37 CFR 1.482) \$700.00 X\$630.00</p> <p>No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$770.00 X\$720.00</p> <p>Neither international preliminary examination fee (37 CFR 1.482) nor \$1040.00 international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$1040.00</p> <p>International preliminary examination fee paid to USPTO (37 CFR 1.482) \$96.00 and all claims satisfied provisions of PCT Article 33(2)-(4) X\$94.00</p>																						
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$ 910.00																				
<p>Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)). \$ 130.00</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 15%;">CLAIMS</th> <th style="width: 25%;">NUMBER FILED</th> <th style="width: 25%;">NUMBER EXTRA</th> <th style="width: 25%;">RATE</th> </tr> </thead> <tbody> <tr> <td>Total claims</td> <td>48 - 20 =</td> <td>28</td> <td>X \$22.00</td> </tr> <tr> <td>Independent claims</td> <td>8 - 3 =</td> <td>5</td> <td>X \$78.00 \$ 400.00</td> </tr> <tr> <td colspan="2">MULTIPLE DEPENDENT CLAIM(S) (if applicable)</td> <td></td> <td>+ \$250.00</td> </tr> <tr> <td colspan="2"></td> <td></td> <td>\$</td> </tr> </tbody> </table>			CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	Total claims	48 - 20 =	28	X \$22.00	Independent claims	8 - 3 =	5	X \$78.00 \$ 400.00	MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$250.00				\$
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE																			
Total claims	48 - 20 =	28	X \$22.00																			
Independent claims	8 - 3 =	5	X \$78.00 \$ 400.00																			
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$250.00																			
			\$																			
TOTAL OF ABOVE CALCULATIONS =		\$2056.00																				
<p>Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28). \$</p>																						
SUBTOTAL =		\$2056.00																				
<p>Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)). \$ -----</p>																						
TOTAL NATIONAL FEE =		\$2056.00																				
<p>Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property \$ -----</p>																						
TOTAL FEES ENCLOSED =		\$2056.00																				
		Amount to be: refunded charged																				
<p>a. <input checked="" type="checkbox"/> A check in the amount of \$ 2056.00 to cover the above fees is enclosed. <input checked="" type="checkbox"/> A check in the amount of \$1290.00 to cover the Petition to Revive fee is also enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 12-0080. A duplicate copy of this sheet is enclosed.</p>																						
<p>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</p>																						
<p>SEND ALL CORRESPONDENCE TO:</p> <p>Jane E. REMILLARD, Esq. Lahive & Cockfield 60 State Street Boston, MA 02109 United States of America phone: (617) 227-7400</p> <p style="text-align: right;">11/20/96 <i>Jane Remillard</i></p> <p>SIGNATURE: _____ Jane E. Remillard NAME _____ 38,872 REGISTRATION NUMBER _____</p>																						

Rec'd PCT/US 20 NOV 1996

08/737904

T CELL EPITOPES OF RYEGRASS POLLEN ALLERGEN

Background of the Invention:

Allergens constitute the most abundant proteins of grass pollen, which is the major cause
5 of allergic disease in temperate climates (Marsh (1975) Allergens and the genetics of allergy; in M. Sela (ed.), *The Antigens*, Vol. 3, pp 271-359, Academic Press Inc., London, New York), Hill et al. (1979) *Medical Journal of Australia*, 1:426-429). The first descriptions of the allergenic proteins in ryegrass showed that they are immunochemically distinct, and are known as groups I,
10 II, III and IV (Johnson and Marsh (1965) *Nature*, 206:935-942; and Johnson and Marsh (1966) *Immunochemistry*, 3:91-100). Using the International Union of Immunological Societies' (IUIS) nomenclature, these allergens are designated *Lol p I*, *Lol p II*, *Lol p III* and *Lol p IV*. In addition, another important *Lolium perenne L.* allergen that has been identified in the literature is *Lol p IX* which is also known as *Lol p V* or *Lol p Ib* (Singh et al. (1991) *Proc. Natl. Acad. Sci. USA*, 88:1384-1388).

15 These five proteins have been identified in pollen ryegrass, *Lolium perenne L.*, and act as antigens in triggering immediate (Type 1) hypersensitivity in susceptible humans.

20 *Lol p V* is defined as an allergen because of its ability to bind to specific IgE in sera of ryegrass-sensitive patients, to act as an antigen in IgG responses and to trigger T-cell responses. The allergenic properties have been demonstrated by immunoblotting studies showing 80% of ryegrass pollen sensitive patients possessed specific IgE antibody that bound to *Lol p V* isoforms (PCT application publication number WO 93/04174, page 65). These results indicate that *Lol p V* is a major ryegrass allergen.

25 Substantial allergenic cross-reactivity between grass pollens has been demonstrated using an IgE-binding assay, the radioallergo-sorbent test (RAST), for example, as described by Marsh et al. (1970) *J. Allergy*, 46, 107-121, and Lowenstein (1978) *Prog. Allergy*, 25, 1-62. (Karger, Basel).

30 The immunochemical relationship of *Lol p V* with other grass pollen antigens have been demonstrated using both polyclonal and monoclonal antibodies (Zhang et al., *Int. Arch Allergy Appl Immunol*, 96:28-34 (1991); Roberts et al., *Int. Arch Allergy Appl Immunol*, 98:178-180 (1992); Mattheisen and Lowenstein, *Clinical and Experimental Allergy*, 21:309-320 (1991); and van Ree et al., *J. Allergy Clin. Immunol.* 83:144-151 (1989)). Antibodies have been prepared to purified proteins that bind IgE components. These data demonstrate that a major allergen is present in pollen of closely related grasses is immunochemically similar to *Lol p V* and are generally characterized as Group V allergens.

In view of the prevalence of ryegrass pollen allergens and related grass allergens all over the world, there is a pressing need for the development of compositions and methods that could be used in detecting sensitivities to *Lol p V* or other immunologically related grass allergens, or in treating sensitivities to such allergens, or in assisting in the manufacture of medicaments to treat such sensitivities. The present invention provides materials and methods having one or more of those utilities.

Summary of the Invention

The present invention provides isolated peptides of *Lol p V*. Peptides within the scope of the invention comprise at least one T cell epitope, preferably at least two T cell epitopes of *Lol p V*. The invention further provides peptides comprising at least two regions, each region comprising at least one T cell epitope of *Lol p V*.

The invention also provides modified peptides having similar or enhanced therapeutic properties as the corresponding, naturally-occurring allergen or portion thereof, but having reduced side effects, as well as modified peptides having improved properties such as increased solubility and stability. Therapeutic peptides of the invention are capable of modifying, in a *Lol p V*-sensitive individual to whom they are administered, the allergic response of the individual to *Lol p V* or an allergen immunologically cross-reactive *Lol p V* e.g. allergens derived from pollen belonging to the Poacea (Graminae) family such as *Dactylis glomerata*, *Dac g V*.

Methods of treatment or of diagnosis of sensitivity to ryegrass pollen protein, *Lol p V* in an individual or to pollen proteins that are immunologically related to *Lol p V* such as *Dac g V*, and therapeutic compositions comprising one or more peptides of the invention are also provided.

The present invention also provides nucleic and amino acid sequences of *Dac g V* protein allergen which is immunologically cross-reactive with *Lol p V*.

Further features of the present invention will be better understood from the following detailed description of the preferred embodiments of the invention in conjunction with the appended figures.

30

Brief Description of the Figures

Fig. 1 shows the nucleotide sequence of cDNA clone 12R (SEQ ID NO:1) and its predicted amino acid sequence (SEQ ID NO:2). Clone 12R is a full-length clone of *Lol p V* derived from a λgtII library (see PCT application publication number WO93/04174).

Fig. 2 shows peptides of the invention of various lengths derived from *Lol p V* (SEQ ID NO:3-29).

Fig. 3 shows peptides of various lengths derived from *Lol p I* (SEQ ID NO:30-53).

Fig. 4 is a graphic representation depicting the response of T cell lines from 19 patients primed *in vitro* with affinity purified *Lol p V* and analyzed for response to *Lol p V* peptides (derived from the *Lol p V* protein allergen) by percent of responses with a mean S.I. of at least 2 (indicated above each bar), the numbers enclosed in the parenthesis denote percentage of patients responding to the particular peptide, and the bar represents the positivity index for each peptide (% of patients responding multiplied by the mean S.I.).

Fig. 5 is a graphic representation derived from the same data shown in Fig. 4 showing the ranked sum for each peptide, the bar represents the cumulative rank of the peptide response in the group of 19 patients tested, above each bar in parenthesis is the percent of patients positively responding to each peptide, the S.I. is also indicated above each bar.

Fig. 6 is a graphic representation of the results of a direct ELISA, the source of IgE was a sample of pooled human plasma (PHP) designated PHP-A, and wherein the antigen is either soluble pollen extract (SPE) of ryegrass pollen, or bacterially expressed recombinant *Lol p V* (r*LolpV*).

Fig. 7 is a graphic representation of the results of a direct ELISA, the source of IgE was a sample of pooled human plasma (PHP) designated PHP-B and wherein the antigen is either soluble pollen extract (SPE) of ryegrass pollen, r*Lol p V*.

Fig. 8 is a graphic representation of the results of a direct ELISA, the source of IgE was plasma from 4 individual patients, #1118, #1120, #1125, #1141, and wherein the antigen is ryegrass pollen SPE.

Fig. 9 is a graphic representation of the results of a direct ELISA the source of IgE was plasma from 4 individual patients, #1118, #1120, #1125, #1141, and wherein the antigen is r*Lol p V*.

Fig. 10 is a graphic representation of the results of a competition ELISA, the source of IgE was a sample of pooled human plasma designated PHP-A, IgE binding was measured in the presence of ryegrass pollen SPE, affinity purified native *Lol p V* or r*Lol p V*.

Fig. 11 is a graphic representation of the results of a competition ELISA, the source of IgE was plasma from individual patient #706 as a source of IgE, IgE binding was measured in the presence of ryegrass pollen SPE, affinity purified *Lol p V* or r*Lol p V*.

Fig. 12 is a graphic representation of a histamine release assay to ryegrass pollen SPE and r*Lol p V*.

Fig. 13a and Fig. 13b each show a graphic representation of a direct ELISA using a sample of pooled human plasma designated PHP-B as a source of IgE, and wherein the antigen was either a selected peptide derived from *Lol p V* or r*Lol p V*.

Fig. 14 is a graphic representation of a competition ELISA using a sample of pooled 5 human plasma designated PHP-B as a source of IgE, and wherein the antigens were a mixture of affinity purified *Lol p I* and *Lol p V* or a mixture of recombinant *Lol p I* (r*Lol p I*) or r*Lol p V* to compete for IgE binding to ryegrass pollen SPE.

Fig. 15 is a photograph of a Coomassie blue stained SDS-PAGE (12.5%) analysis of an 10 Ab1B9-affinity purified native *Lol p V*, the sample was run under reducing conditions, the molecular weight standards are shown on the left.

Fig. 16 shows the nucleotide sequence of clone 259 of *Dac g V*, and its predicted amino acid sequence, the nucleotide sequence of nucleotides 1 to 699 has been confirmed, and the nucleotide sequence of nucleotides 700 to 1181 are unconfirmed.

15 **Detailed Description of the Invention**

The present invention provides isolated peptides derived from *Lol p V*. The present invention also provides *Dac g V* protein allergen which is immunologically cross-reactive with *Lol p V*. As used herein, a "peptide" refers to any protein fragment of *Lol p V* that induces an immune response. The terms "fragment" and "antigenic fragment" as used herein refer to an 20 amino acid sequence having fewer amino acid residues than the entire amino acid sequence of the protein from which the fragment is derived, and that induces an immune response. The terms "isolated" and "purified" as used herein refer to peptides of the invention which are substantially free of cellular material or culture medium when produced by recombinant DNA techniques, or substantially free of chemical precursors or other chemicals when synthesized 25 chemically. As used herein, the term "peptide" of the invention include peptides derived from *Lol p V* which comprise at least one T cell epitope of the allergen or a portion of such peptide which comprises at least one T cell epitope.

Peptides comprising at least two regions, each region comprising at least one T cell epitope of *Lol p V* are also within the scope of the invention. Isolated peptides or regions of 30 isolated peptides, each comprising at least two T cell epitopes of *Lol p V* protein allergen are particularly desirable for increased therapeutic effectiveness. Peptides which are immunologically related (e.g., by antibody or T cell cross-reactivity) to peptides of the present invention, such as peptides from *Dac g V*, are also within the scope of the invention. Peptides immunologically related by antibody cross-reactivity, are bound by antibodies specific for a

peptide of *Lol p* V. Peptides immunologically related by T cell cross-reactivity are capable of reacting with the same T cells as a peptide of the invention.

Isolated peptides of the invention can be produced by recombinant DNA techniques in a host cell transformed with a nucleic acid having a sequence encoding such peptide. The isolated peptides of the invention can also be produced by chemical synthesis. When a peptide is produced by recombinant techniques, host cells transformed with a nucleic acid having a sequence encoding a peptide of the invention or the functional equivalent of the nucleic acid sequence are cultured in a medium suitable for the cells and peptides can be purified from cell culture medium, host cells, or both using techniques known in the art for purifying peptides and proteins including ion-exchange chromatography, gel filtration chromatography, ultrafiltration, electrophoresis or immunopurification with antibodies specific for the peptide, the protein allergen from which the peptide is derived, or a portion thereof.

The present invention provides expression vectors and host cells transformed to express the nucleic acid sequences of the invention. Nucleic acid coding for a *Lol p* V peptide of the invention or at least one fragment thereof may be expressed in bacterial cells such as *E. coli*, insect cells, yeast, or mammalian cells such as Chinese hamster ovary cells (CHO). Suitable expression vectors, promoters, enhancers, and other expression control elements may be found in Sambrook et al. *Molecular Cloning: A Laboratory Manual*, second edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989. Other suitable expression vectors, promoters, enhancers, and other expression elements are known to those skilled in the art. Suitable vectors for expression in yeast include YepSec1 (Baldari et al. (1987) *Embo J.* **6**: 229-234); pMFa (Kurjan and Herskowitz (1982) *Cell* **30**: 933-943); JRY88 (Schultz et al. (1987) *Gene* **54**: 113-123) and pYES2 (Invitrogen Corporation, San Diego, CA). These vectors are freely available. Baculovirus and mammalian expression systems are also available. For example, a baculovirus system is commercially available (PharMingen, San Diego, CA) for expression in insect cells while the pMSG vector is commercially available (Pharmacia, Piscataway, NJ) for expression in mammalian cells.

For expression in *E. coli*, suitable expression vectors include, among others, pTRC (Amann et al. (1988) *Gene* **69**: 301-315); pGEX (Amrad Corp., Melbourne, Australia); pMAL (N.E. Biolabs, Beverly, MA); pRIT5 (Pharmacia, Piscataway, NJ); pET-11d (Novagen, Madison, WI) Jameel et al., (1990) *J. Virol.* **64**:3963-3966; and pSEM (Knapp et al. (1990) *BioTechniques* **8**: 280-281). The use of pTRC, and pET-11d, for example, will lead to the expression of unfused protein. The use of pMAL, pRIT5 pSEM and pGEX will lead to the expression of allergen fused to maltose E binding protein (pMAL), protein A (pRIT5), truncated

β-galactosidase (PSEM), or glutathione S-transferase (pGEX). When a *Lol p* V peptide of the invention is expressed as a fusion protein, it is particularly advantageous to introduce an enzymatic cleavage site at the fusion junction between the carrier protein and *Lol p* V peptide. The *Lol p* V peptide may then be recovered from the fusion protein through enzymatic cleavage 5 at the enzymatic site and biochemical purification using conventional techniques for purification of proteins and peptides. Suitable enzymatic cleavage sites include those for blood clotting Factor Xa or thrombin for which the appropriate enzymes and protocols for cleavage are commercially available from, for example, Sigma Chemical Company, St. Louis, MO and N.E. Biolabs, Beverly, MA. The different vectors also have different promoter regions allowing 10 constitutive or inducible expression with, for example, IPTG induction (PRTC, Amann et al., (1988) *supra*; pET-11d, Novagen, Madison, WI) or temperature induction (pRIT5, Pharmacia, Piscataway, NJ). It may also be appropriate to express recombinant *Lol p* V peptides in 15 different *E. coli* hosts that have an altered capacity to degrade recombinantly expressed proteins (e.g. U.S. patent 4,758,512). Alternatively, it may be advantageous to alter the nucleic acid sequence to use codons preferentially utilized by *E. coli*, where such nucleic acid alteration would not affect the amino acid sequence of the expressed protein.

Host cells can be transformed to express the nucleic acid sequences of the invention using conventional techniques such as calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, or electroporation. Suitable methods for transforming the host 20 cells may be found in Sambrook et al. *supra*, and other laboratory textbooks. The nucleic acid sequences of the invention may also be chemically synthesized using standard techniques (i.e. solid phase synthesis). Details of the isolation and cloning of clone 12R encoding *Lol p* V (described as *Lol p* Ib.1) are given in PCT application Publication Number WO 93/04174 incorporated herein by reference in its entirety.

25 Inducible non-fusion expression vectors include pTrc (Amann et al., (1988) *Gene*, 69:301-315) and pET11d (Studier et al., *Gene Expression Technology: Methods in Enzymology*, Academic Press, San Diego, California (1990), 185:60-89). While target gene expression relies on host RNA polymerase transcription from the hybrid trp-lac fusion promoter in pTrc, expression of target genes inserted into pET11d relies on transcription from the T7 gn10-lac 0 30 fusion promoter mediated by coexpressed viral RNA polymerase (T7 gn1). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident λ prophage harboring a T7 gn1 under the transcriptional control of the lacUV 5 promoter.

One strategy to maximize recombinant *Lol p* V peptide expression in *E. coli* is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant

protein (Gottesman, S., *Gene Expression Technology: Methods in Enzymology*, Academic Press, San Diego, California (1990), 185:119-128). Another strategy would be to alter the nucleic acid sequence of the desired gene to be inserted into an expression vector so that the individual codons for each amino acid would be those preferentially utilized in highly expressed *E. coli* 5 proteins (Wada *et al.* (1992) *Nuc. Acids Res.*, 20:2111-2118). Such alteration of nucleic acid sequences of the invention could be carried out by standard DNA synthesis techniques.

The nucleic acids of the invention can also be chemically synthesized using standard techniques. Various methods of chemically synthesizing polydeoxynucleotides are known, including solid-phase synthesis which, like peptide synthesis, has been fully automated in 10 commercially available DNA synthesizers (See e.g., Itakura *et al.* U.S. Patent 4,598,049; Caruthers *et al.* U.S. Patent 4,458,066; and Itakura U.S. Patents 4,401,796 and 4,373,071, incorporated by reference herein).

The present invention also provides nucleic acid sequences encoding peptides of the invention. Nucleic acid sequences used in any embodiment of this invention can be cDNAs 15 encoding corresponding peptide sequences as shown in Fig. 2 (SEQ ID NO:3-29). Such oligodeoxynucleotide sequences can be produced chemically or mechanically, using known techniques. A functional equivalent of an oligonucleotide sequence is one which is 1) a sequence capable of hybridizing to a complementary oligonucleotide to which the sequence (or corresponding sequence portions) of *Lol p V* as shown in Fig. 1 or fragments thereof hybridizes, 20 or 2) the sequence (the corresponding sequence portions complementary to the nucleic acid sequences encoding the peptide sequence derived from *Lol p V*, as shown in Fig. 2 and/or 3) a sequence which encodes a product (e.g., a polypeptide or peptide) having the same functional characteristics of the product encoded by the sequence (or corresponding sequence portion) of *Lol p V* as shown in Fig. 1. Whether a functional equivalent must meet one or more criteria will 25 depend on its use (e.g., if it is to be used only as an oligoprobe, it need meet only the first or second criteria and if it is to be used to produce a *Lol p V* peptide of the invention, it need only meet the third criterion). The nucleic acid sequences of the invention also include RNA which can be transcribed from the DNA prepared as described above.

Preferred nucleic acids encode a peptide having at least about 50% homology to a *Lol p V* 30 peptide of the invention, more preferably at least about 60% homology and most preferably at least about 70% homology with a *Lol p V* peptide of the invention. Nucleic acids that encode peptides having at least about 90%, more preferably at least about 95%, and most preferably at least about 98-99% homology with *Lol p V* peptides of the invention are also within the scope of the invention. Homology refers to sequence similarity between two peptides of *Lol p V*, or

between two nucleic acid molecules. Homology can be determined by comparing a position in each sequence which may be aligned for purposes of comparison. When a position in the compared sequence is occupied by the same nucleotide or amino acid, then molecules are homologous at that position. A degree of homology between sequences is a function of the
5 number of matching or homologous positions shared by the sequences.

Preferred nucleic acid fragments encode peptides of at least 7 amino acid residues in length, and preferably 13-40 amino acid residues in length, and more preferably at least 16-30 amino acids residues in length. Nucleic acid fragments encoding peptides of at least 30 amino acid residues in length, at least 40 amino acid residues in length, at least about 80-amino acid
10 residues in length, at least about 100 amino acid residues in length or more, are also contemplated.

Also within the scope of the invention are nucleic acid sequences encoding allergens immunologically cross-reactive with *Lol p V*, such as full length *Dac g V* protein or peptides (Fig. 16). Proteins and peptides of *Dac g V* may be produced recombinantly as discussed above,
15 or synthetically. Expression vectors and host cells transformed to express *Dac g V* protein or peptides thereof are also within the scope of the invention. Details of the cloning of *Dac g V* are given in the examples.

The present invention also provides a method of producing isolated *Lol p V* peptides of the invention or a portion thereof comprising the steps of culturing a host cell transformed with a
20 nucleic acid sequence encoding a *Lol p V* peptide of the invention in an appropriate medium to produce a mixture of cells and medium containing said *Lol p V* peptide; and purifying the mixture to produce substantially pure *Lol p V* peptide. Host cells transformed with an expression vector containing DNA coding for a *Lol p V* peptide of the invention or a portion thereof are cultured in a suitable medium for the host cell. *Lol p V* peptides of the invention can be purified
25 from cell culture medium, host cells, or both using techniques known in the art for purifying peptides and proteins including ion-exchange chromatography, gel filtration chromatography, ultrafiltration, electrophoresis and immunopurification with antibodies specific for the *Lol p V* peptides or portions thereof of the invention.

Another aspect of the present invention pertains to an antibody specifically reactive with
30 a *Lol p V* peptide. Such antibodies may be used to standardize allergen extracts or to isolate the naturally occurring *Lol p V*. Also, *Lol p V* peptides of the invention can be used as "purified" allergens to standardize allergen extracts. For example, an animal such as a mouse or rabbit can be immunized with an immunogenic form of an isolated *Lol p V* peptide of the invention capable of eliciting an antibody response. Techniques for conferring immunogenicity on a

peptide include conjugation to carriers or other techniques well-known in the art. The *Lol p V* peptide also can be administered in the presence of adjuvant. The progress of immunization can be monitored by detection of antibody titers in plasma or serum standard ELISA or other immunoassay can be used with the immunogen as antigen to assess the levels of antibodies.

5 Following immunization, anti-*Lol p V* peptide antisera can be obtained and, if desired, polyclonal anti-*Lol p V* peptide antibodies from the serum. To produce monoclonal antibodies, antibody producing cells (lymphocytes) can be harvested from an immunized animal and fused by standard somatic cell fusion procedures with immortalizing cells such as myeloma cells to yield hybridoma cells. Hybridoma cells can be screened immunochemically for production of
10 antibodies reactive with the *Lol p V* peptides of the invention. These sera or monoclonal antibodies can be used to standardize allergen extracts.

Through use of the peptides and antibodies of the present invention, preparations of consistent, well-defined composition and biological activity can be made and administered for therapeutic purposes (e.g. to modify the allergic response of a ryegrass pollen sensitive individual
15 to pollen of such grasses or pollen of an immunologically related grass such as *Dac g V*). Administration of such peptides may, for example, modify B-cell response to *Lol p V* allergen, T-cell response to *Lol p V* allergen or both responses. Isolated peptides can also be used to study the mechanism of immunotherapy of ryegrass pollen allergy and to design modified derivatives or analogues useful in immunotherapy.

20 The present invention also pertains to T cell clones which specifically recognize *Lol p V* peptides of the invention. These T cell clones may be suitable for isolation and molecular cloning of the gene for the T cell receptor which is specifically reactive with a peptide of the present invention. The T cell clones may be produced as described in *Cellular and Molecular Immunology*, Abdul K. Abbas et al., W.B. Saunders Co. (1991) pg. 139. The present invention
25 also pertains to soluble T cell receptors. These receptors may inhibit antigen-dependent activation of the relevant T cell subpopulation within an individual sensitive to *Lol p V*. Antibodies specifically reactive with such a T cell receptor can also be produced according to the techniques described herein. Such antibodies may also be useful to block T-cell -MHC interaction in an individual. Methods for producing soluble T cell receptors are described in
30 *Immunology; A Synthesis*, 2nd Ed., Edward S. Golub et al., Sinaur Assoc, Sunderland Massachusetts, (1991) pp. 366-369..

To obtain isolated peptides of the present invention, *Lol p V* is divided into non-overlapping peptides of desired length or overlapping peptides of desired lengths as discussed in Example 2 which can be produced recombinantly, synthetically, or in certain situations, by

chemical cleavage of the allergen. Peptides comprising at least one T cell epitope are capable of eliciting a T cell response, such as stimulation (i.e. proliferation or lymphokine secretion) and/or are capable of inducing T cell non-responsiveness. To determine peptides comprising at least one T cell epitope, isolated peptides are tested by, for example, T cell biology techniques, to 5 determine whether the peptides elicit a T cell response or induce T cell non-responsiveness. Those peptides found to elicit a T cell response or induce T cell non-responsiveness are defined as having T cell stimulating activity.

Screening peptides of the invention for human T cell stimulating activity can be accomplished using one or more of several different assays. For example, *in vitro*, T cell 10 stimulatory activity is assayed by contacting a peptide of the invention with an antigen presenting cell which presents appropriate MHC molecules in a T cell culture. Presentation of a peptide of the invention in association with appropriate MHC molecules to T cells, in conjunction with the necessary costimulation has the effect of transmitting a signal to the T cell that induces the production of increased levels of cytokines, particularly of interleukin-2 and 15 interleukin-4. The culture supernatant can be obtained and assayed for interleukin-2 or other known cytokines. For example, any one of several conventional assays for interleukin-2 can be employed, such as the assay described in *Proc. Natl. Acad. Sci USA*, **86**:1333 (1989) the pertinent portions of which are incorporated herein by reference. A kit for an assay for the production of interferon is also available from Genzyme Corporation (Cambridge, MA).

20 A common assay for T cell proliferation entails measuring tritiated thymidine incorporation. The proliferation of T cells can be measured *in vitro* by determining the amount of ³H-labeled thymidine incorporated into the replicating DNA of cultured cells. Therefore, the rate of DNA synthesis and, in turn, the rate of cell division can be quantified.

A peptide may also be screened for the ability to reduce T cell responsiveness. The 25 ability of a peptide known to stimulate T cells, to inhibit or completely block the activity of a purified native *Lol p V* protein allergen or portion thereof and induce a state of T cell nonresponsiveness or reduced T cell responsiveness, can be determined using subsequent attempts at stimulation of the T cells with antigen presenting cells that present a native *Lol p V* allergen following exposure to a peptide of the invention. If the T cells are unresponsive to the 30 subsequent activation attempts, as determined by interleukin-2 synthesis and T cell proliferation, a state of nonresponsiveness has been induced. See, e.g., Gimmi, et al. (1993) *Proc. Natl. Acad. Sci USA*, **90**:6586-6590; and Schwartz (1990) *Science*, **248**:1349-1356, for assay systems that can be used as the basis for an assay in accordance with the present invention.

Additionally, peptides comprising "cryptic epitopes" may be determined and are also within the scope of this invention. Cryptic epitopes are those determinants in a protein antigen which, due to processing and presentation of the native protein antigen to the appropriate MHC molecule, are not normally revealed to the immune system. However, a peptide comprising a 5 cryptic epitope is capable of causing T cells to become non-responsive, and when a subject is primed with the peptide, T cells obtained from the subject will proliferate *in vitro* in response to the peptide or the protein antigen from which the peptide is derived. Peptides which comprise at least one cryptic epitope derived from a protein antigen are referred to herein as "cryptic peptides". To confirm the presence of cryptic epitopes in the above-described T cell 10 proliferation assay, antigen-primed T cells are cultured *in vitro* in the presence of each peptide separately to establish peptide-reactive T cell lines. A peptide is considered to comprise at least one cryptic epitope if a T cell line can be established with a given peptide and T cells are capable of proliferation upon challenge with the peptide and the protein antigen from which the peptide is derived.

15 It is also possible to modify the structure of a peptide of the invention for such purposes as increasing solubility, enhancing therapeutic or preventive efficacy, or stability (e.g., shelf life *ex vivo*, and resistance to proteolytic degradation *in vivo*). A modified peptide can be produced in which the amino acid sequence has been altered, such as by amino acid substitution, deletion, or addition, to modify immunogenicity and/or reduce allergenicity, or to which a component has 20 been added for the same purpose.

For example, a peptide can be modified so that it maintains the ability to induce T cell 25 anergy and bind MHC proteins without the ability to induce a strong proliferative response or possibly, any proliferative response when administered in immunogenic form. In this instance, critical binding residues for the T cell receptor can be determined using known techniques (e.g., substitution of each residue and determination of the presence or absence of T cell reactivity). Those residues shown to be essential to interact with the T cell receptor can be modified by 30 replacing the essential amino acid with another, preferably similar amino acid residue (a conservative substitution) whose presence is shown to enhance, diminish but not eliminate, or not affect T cell reactivity. In addition, those amino acid residues which are not essential for T cell receptor interaction can be modified by being replaced by another amino acid whose incorporation may enhance, diminish or not affect T cell reactivity but does not eliminate binding to relevant MHC.

Additionally, peptides of the invention can be modified by replacing an amino acid shown to be essential to interact with the MHC protein complex with another, preferably similar

PAPERS REFERRED TO IN THIS APPLICATION

amino acid residue (conservative substitution) whose presence is shown to enhance, diminish but not eliminate, or not affect T cell activity. In addition, amino acid residues which are not essential for interaction with the MHC protein complex but which still bind the MHC protein complex can be modified by being replaced by another amino acid whose incorporation may 5 enhance, not affect, or diminish but not eliminate T cell reactivity. Preferred amino acid substitutions for non-essential amino acids include, but are not limited to substitutions with alanine, glutamic acid, or a methyl amino acid.

In order to enhance stability and/or reactivity, peptides of the invention can also be modified to incorporate one or more polymorphisms in the amino acid sequence of the protein 10 allergen resulting from natural allelic variation. Additionally, D-amino acids, non-natural amino acids or non-amino acid analogues can be substituted or added to produce a modified peptide within the scope of this invention. Furthermore, peptides of the present invention can be modified using the polyethylene glycol (PEG) method of A. Sehon and co-workers (Wie et al. 15 *supra*) to produce a protein or peptide conjugated with PEG. In addition, PEG can be added during chemical synthesis of a protein or peptide of the invention. Modifications of peptides or portions thereof can also include reduction/ alkylation (Tarr in: *Methods of Protein Microcharacterization*, J.E. Silver ed. Humana Press, Clifton, NJ, pp 155-194 (1986)); acylation (Tarr, *supra*); chemical coupling to an appropriate carrier (Mishell and Shiigi, eds., *Selected Methods in Cellular Immunology*, WH Freeman, San Francisco, CA (1980); U.S. Patent 20 4,939,239; or mild formalin treatment (Marsh, *International Archives of Allergy and Applied Immunology*, 41:199-215 (1971)).

To facilitate purification and potentially increase solubility of peptides of the invention, it is possible to add reporter group(s) to the peptide backbone. For example, poly-histidine can be added to a peptide to purify the peptide on immobilized metal ion affinity chromatography 25 (Hochuli, E. et al., *Bio/Technology*, 6:1321-1325 (1988)). In addition, specific endoprotease cleavage sites can be introduced, if desired, between a reporter group and amino acid sequences of a peptide to facilitate isolation of peptides free of irrelevant sequences. In order to successfully desensitize an individual to a protein antigen, it may be necessary to increase the solubility of a peptide by adding functional groups to the peptide or by not including 30 hydrophobic T cell epitopes or regions containing hydrophobic epitopes in the peptides or hydrophobic regions of the protein or peptide. Functional groups such as charged amino acid pairs (e.g., KK or RR) are particularly useful for increasing the solubility of a peptide when added to the amino or carboxy terminus of the peptide.

To potentially aid proper antigen processing of T cell epitopes within a peptide, canonical protease sensitive sites can be recombinantly or synthetically engineered between regions, each comprising at least one T cell epitope. For example, charged amino acid pairs, such as KK or RR, can be introduced between regions within a peptide during recombinant construction of the peptide. The resulting peptide can be rendered sensitive to cathepsin and/or other trypsin-like enzymes cleavage to generate portions of the peptide containing one or more T cell epitopes. In addition, as discussed above, such charged amino acid residues can be added to the amino or carboxy terminus of the peptide and can result in an increase in solubility of a peptide.

Site-directed mutagenesis of DNA encoding a peptide of the invention can be used to modify the structure of the peptide by methods known in the art. Such methods may, among others, include PCR with oligonucleotides containing the sequences encoding the desired amino acids (Ho et al., *Gene*, 77:51-59 (1989)) or total synthesis of mutated genes (Hostomsky, Z. et al., *Biochem. Biophys. Res. Comm.*, 161:1056-1063 (1989)). To enhance bacterial expression, the aforementioned methods can be used in conjunction with other procedures to change the eukaryotic codons in DNA constructs encoding protein or peptides of the invention to ones preferentially used in *E. coli*, yeast, mammalian cells, or other eukaryotic cells.

Peptides or antibodies of the present invention can also be used for detecting and diagnosing ryegrass pollinosis. For example, this could be done *in vitro* by combining blood or blood products obtained from an individual to be assessed for sensitivity to ryegrass pollen or another cross reactive pollen such as *Dac g V*, with isolated peptides of *Lol p V*, under conditions appropriate for binding of components in the blood (e.g., antibodies, Tcells, B cells) with the peptide(s) and determining the extent to which such binding occurs. Other diagnostic methods for allergic diseases in which the protein, peptides or antibodies of the present invention will be useful include radio-allergosorbent test (RAST), paper radioimmunosorbent test (PRIST), enzyme linked immunosorbent assay (ELISA), radioimmunoassays (RIA), immuno-radiometric assays (IRMA), luminescence immunoassays (LIA), histamine release assays and IgE immunoblots.

The presence in individuals of IgE specific for at least one protein allergen and the ability of T cells of the individuals to respond to T cell epitope(s) of the protein allergen can be determined by administering to the individuals an Immediate Type Hypersensitivity test and a Delayed Type Hypersensitivity test. The individuals are administered an Immediate Type Hypersensitivity test (see e.g., *Immunology* (1985) Roitt, I.M., Brostoff, J., Male, D.K. (eds), C.V. Mosby Co., Gower Medical Publishing, London, NY, pp. 19.2-19.18; pp. 22.1-22.10) utilizing the protein allergen or a portion thereof, or a modified form of the protein allergen or a

portion thereof, each of which binds IgE specific for the allergen. The same individuals are administered a Delayed Type Hypersensitivity test prior to, simultaneously with, or subsequent to administration of the Immediate Type Hypersensitivity test. Of course, if the Immediate Type Hypersensitivity test is administered prior to the Delayed Type Hypersensitivity test, the Delayed
5 Type Hypersensitivity test would be given to those individuals exhibiting a specific Immediate Type Hypersensitivity reaction. The Delayed Type Hypersensitivity test utilizes a modified form of the protein allergen or a portion thereof, the protein allergen produced recombinantly, or a peptide derived from the protein allergen, each of which has human T cell stimulating activity and each of which does not bind IgE specific for the allergen in a substantial percentage of the
10 population of individuals sensitive to the allergen (e.g., at least about 75%). Those individuals found to have both a specific Immediate Type Hypersensitivity reaction and a specific Delayed Type Hypersensitivity reaction may be treated with a therapeutic composition comprising the same modified form of the protein or portion thereof, the recombinantly produced protein allergen, or the peptide, each as used in the Delayed Type Hypersensitivity test.

15 Isolated peptides of the invention when administered in a therapeutic regimen to a *Lol p* V-sensitive individual, or an individual allergic to an allergen cross-reactive with *Lol p* V such as *Dac g* V, are capable of modifying the allergic response of the individual to *Lol p* V ryegrass pollen allergen or such cross-reactive allergen, and preferably are capable of modifying the B-cell response, T-cell response or both the B-cell and the T-cell response of the individual to the
20 allergen. As used herein, modification of the allergic response of an individual sensitive to a ryegrass pollen allergen or cross-reactive allergen can be defined as non-responsiveness or diminution in symptoms to the allergen, as determined by standard clinical procedures (See e.g. Varney et al, *British Medical Journal*, 302:265-269 (1990)) including diminution in ryegrass pollen induced asthmatic symptoms. As referred to herein, a diminution in symptoms includes
25 any reduction in the allergic response of an individual to the allergen after the individual has completed a treatment regimen with a peptide or protein of the invention. This diminution may be subjective (i.e. the patient feels more comfortable in the presence of the allergen). Diminution in symptoms can be determined clinically as well, using standard skin tests as is known in the art.

30 *Lol p* V peptides of the present invention which have T cell stimulating activity, and thus comprise at least one T cell epitope are particularly desirable for therapeutic purposes. In referring to an epitope, the epitope will be the basic element or smallest unit of recognition by a receptor, particularly immunoglobulins, histocompatibility antigens and T cell receptors where the epitope comprises amino acids essential to receptor recognition. Amino acid sequences which mimic those of the epitopes and which are capable of down regulating or reducing allergic

response to *Lol p V* can also be used. T cell epitopes are believed to be involved in initiation and perpetuation of the immune response to a protein allergen which is responsible for the clinical symptoms of allergy. These T cell epitopes are thought to trigger early events at the level of the T helper cell by binding to an appropriate HLA molecule on the surface of an antigen presenting cell and stimulating the relevant T cell subpopulation. These events lead to T cell proliferation, lymphokine secretion, local inflammatory reactions, recruitment of additional immune cells to the site, and activation of the B cell cascade leading to production of antibodies. One isotype of these antibodies, IgE, is fundamentally important to the development of allergic symptoms and its production is influenced early in the cascade of events, at the level of the T helper cell, by the nature of the lymphokines secreted.

Exposure of ryegrass pollen patients to isolated *Lol p V* peptides of the present invention which comprise at least one T cell epitope and are derived from *Lol p V* protein allergen may cause appropriate T cell subpopulations to become nonresponsive or have a reduced response to the protein allergen and thus do not participate in stimulating an immune response upon such exposure. In addition, administration of a peptide of the invention or portion thereof which comprises at least one T cell epitope may modify the lymphokine secretion profile as compared with exposure to the naturally-occurring *Lol p V* protein allergen or portion thereof (e.g. result in a decrease of IL-4 and/or an increase in IL-2). Furthermore, administration of such peptide of the invention may influence T cell subpopulations which normally participate in the response to the naturally occurring allergen such that these T cells are drawn away from the site(s) of normal exposure to the allergen (e.g., nasal mucosa, skin, and lung) towards the site(s) of therapeutic administration of the fragment or protein allergen. This redistribution of T cell subpopulations may ameliorate or reduce the ability of an individual's immune system to stimulate the usual immune response at the site of normal exposure to the allergen, resulting in a diminution in allergic symptoms.

The isolated *Lol p V* peptides of the invention can be used in methods of diagnosing, treating and preventing allergic reactions to *Lol p V* allergen or a cross reactive protein allergen. Thus the present invention provides compositions useful in allergy diagnosis and/or useful in allergy therapy comprising isolated *Lol p V* peptides or portions thereof. Such compositions will typically also comprise a pharmaceutically acceptable carrier or diluent when intended for *in vivo* administration. Therapeutic compositions of the invention may also comprise synthetically prepared *Lol p V* peptides and a pharmaceutically acceptable carrier or diluent.

Administration of the therapeutic compositions of the present invention to an individual to be desensitized can be carried out using known techniques. *Lol p V* peptides or portions

thereof may be administered to an individual in combination with, for example, an appropriate diluent, a carrier and/or an adjuvant. Pharmaceutically acceptable diluents include saline and aqueous buffer solutions. Pharmaceutically acceptable carriers include polyethylene glycol (Wie et al. (1981) *Int. Arch. Allergy Appl. Immunol.* **64**:84-99) and liposomes (Strejan et al. (1984) *J. Neuroimmunol.*, **7**: 27).

The therapeutic compositions of the invention are administered to ryegrass allergen sensitive individuals or individuals sensitive to an allergen which is immunologically cross-reactive with house ryegrass allergen (i.e. *Dactylis glomerata*, or *Sorghum halepensis*, etc.). For the purposes of inducing T cell non responsiveness, therapeutic compositions of the invention are preferably administered in non-immunogenic form, e.g. which does not contain adjuvant. While not intending to be limited to any theory, it is believed that T cell non responsiveness or reduced T cell responsiveness is induced as a result of not providing an appropriate costimulatory signal sometimes referred to as a "second signal". Briefly, it is believed that stimulation of T cells requires two types of signals, the first is the recognition by the T cell via the T cell receptor of appropriate MHC-associated processed antigens on antigen presenting cells (APCs) and the second type of signal is referred to as a costimulatory signal(s) or "second signal" which may be provided by certain competent APCs. When a composition of the invention is administered without adjuvant, it is believed that competent APCs which are capable of producing the second signal or costimulatory signal are not engaged in the stimulation of appropriate T cells therefore resulting in T cell nonresponsiveness or reduced T cell responsiveness. In addition, there are a number of antibodies or other reagents capable of blocking the delivery of costimulatory signals such as the "second signal" which include, but are not limited to B7 (including B7-1, B7-2, and BB-1), CD28, CTLA4, CD40 CD40L CD54 and CD11a/18 (Jenkins and Johnson, *Current Opinion in Immunology*, **5**:361-367 (1993), and Clark and Ledbetter, *Nature*, **367**:425-428 (1994)). Thus, a peptide of the invention may be administered in nonimmunogenic form as discussed above, in conjunction with a reagent capable of blocking costimulatory signals such that the level of T cell nonresponsiveness is enhanced.

Administration of the therapeutic compositions of the present invention to an individual to be desensitized can be carried out using known procedures at dosages and for periods of time effective to reduce sensitivity (i.e., reduce the allergic response) of the individual to the allergen. Effective amounts of the therapeutic compositions will vary according to factors such as the degree of sensitivity of the individual to ryegrass pollen, the age, sex, and weight of the individual, and the ability of the protein or fragment thereof to elicit an antigenic response in the individual.

2025 TT 4106226280

The active compound (i.e., protein or fragment thereof) may be administered in a convenient manner such as by injection (subcutaneous, intravenous, etc.), oral administration, inhalation, transdermal application, or rectal administration. Depending on the route of administration, the active compound may be coated within a material to protect the compound
5 from the action of enzymes, acids and other natural conditions which may inactivate the compound.

For example, preferably about 1 µg- 3 mg and more preferably from about 20-750 µg of active compound (i.e., protein or fragment thereof) per dosage unit may be administered by injection. Dosage regimen may be adjusted to provide the optimum therapeutic response. For
10 example, several divided doses may be administered daily or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation.

To administer a peptide by other than parenteral administration, it may be necessary to coat the protein with, or co-administer the protein with, a material to prevent its inactivation. For example, peptide or portion thereof may be co-administered with enzyme inhibitors or in
15 liposomes. Enzyme inhibitors include pancreatic trypsin inhibitor, diisopropylfluorophosphate (DEP) and trasyloL. Liposomes include water-in-oil-in-water CGF emulsions as well as conventional liposomes (Strejan *et al.*, (1984) *J. Neuroimmunol.*, 7:27).

The active compound may also be administered parenterally or intraperitoneally. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof
20 and in oils. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions of dispersion. In all cases, the composition must be sterile and must
25 be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glyceral, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The
30 proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars,

RECORDED - 40623280

polyalcohols such as manitol and sorbitol or sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about, including in the composition, an agent which delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating active compound (i.e., 5 protein or peptide) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the 10 preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient (i.e., protein or peptide) plus any additional desired ingredient from a previously sterile-filtered solution thereof.

When a peptide of the invention is suitably protected, as described above, the peptide may be orally administered, for example, with an inert diluent or an assimilable edible carrier. The 15 peptide and other ingredients may also be enclosed in a hard or soft shell gelatin capsule, compressed into tablets, or incorporated directly into the individual's diet. For oral therapeutic administration, the active compound may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 1% by weight of active 20 compound. The percentage of the composition and preparations may, of course, be varied and may conveniently be between about 5 to 80% of the weight of the unit. The amount of active compound in such therapeutically useful compositions is such that a suitable dosage will be obtained. Preferred compositions or preparations according to the present invention are prepared so that an oral dosage unit contains between about 10 µg to about 200 mg of active 25 compound.

The tablets, troches, pills, capsules and the like may also contain the following: a binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring. When the dosage 30 unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar or both. A syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl

and propylparabens as preservative, a dye and flavoring such as cherry or orange flavor. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed. In addition, the active compound may be incorporated into sustained-release preparations and formulations.

5 As used herein "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the therapeutic compositions is contemplated.

10 Supplementary active compounds can also be incorporated into the compositions.

It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired 15 therapeutic effect in association with the required pharmaceutical carrier. The specification for the novel dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active compound for the treatment of sensitivity in individuals.

20 Various isolated peptides of the invention derived from ryegrass pollen protein *Lol p V* are shown in Fig. 2 (SEQ ID NO:3-29). Peptides comprising at least two regions, each region comprising at least one T cell epitope of *Lol p V* are also within the scope of the invention. As used herein a region may include the amino acid sequence of a peptide of the invention as shown in Fig. 2 or the amino acid sequence of a portion of such peptide.

25 As discussed in Example 2, human T cell stimulating activity can be tested by culturing T cells obtained from an individual sensitive to *Lol p V* allergen, (i.e., an individual who has an IgE mediated immune response to *Lol p V* allergen) with a peptide derived from the allergen and determining whether proliferation of T cells occurs in response to the peptide as measured, e.g., by cellular uptake of tritiated thymidine. Stimulation indices for responses by T cells to peptides 30 can be calculated as the maximum CPM in response to a peptide divided by the control CPM. A stimulation index (S.I.) equal to or greater than two times the background level is considered "positive". Positive results are used to calculate the mean stimulation index for each peptide for the group of patients tested. In Figs. 4 and 5 the mean T cell stimulation index is indicated above the bar. Preferred peptides of this invention comprise at least one T cell epitope and have a mean

PENTEK DOCUMENTS

T cell stimulation index of greater than or equal to 2.0. A peptide having a mean T cell stimulation index of greater than or equal to 2.0 in a significant number of ryegrass pollen sensitive patients tested is considered useful as a therapeutic agent. Preferred peptides have a mean T cell stimulation index of at least 2.5, more preferably at least 3.0, more preferably at least 5, more preferably at least 4.0, more preferably at least 5.0 and most preferably at least about 6. For example, peptides of the invention having a mean T cell stimulation index of at least 5, as indicated by data shown in Figs 4 and 5, include peptides LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-8 (SEQ ID NO:10), LPIX-17 (SEQ ID NO:19) and LPIX-19 (SEQ ID NO:21).

In addition, preferred peptides have a positivity index (P.I.) of at least about 60, more preferably about 100, more preferably at least about 200 and most preferably at least about 300. The positivity index for a peptide is determined by multiplying the mean T cell stimulation index by the percent of individuals, in a population of individuals sensitive to ryegrass pollen (e.g., preferably a population of at least 15 individuals, more preferably a population of at least 30 individuals or more), who have a T cell stimulation index to such peptide of at least 2.0. Thus, the positivity index represents both the strength of a T cell response to a peptide (S.I.) and the frequency of a T cell response to a peptide in a population of individuals sensitive to ryegrass pollen. In Fig. 4, the bar represents the positivity index and the percent of individuals tested who have a T cell stimulation index of at least 2.0 to that peptide are indicated in parenthesis above each bar (the mean T cell stimulation index is also indicated above each bar). For example, as shown in Fig. 4, *Lol p V* peptide LPIX-5 (SEQ ID NO:7) has a mean S.I. of 5.8 and 26.3% of positive responses in the group of individuals tested resulting in a positivity index of 152.54. *Lol p V* peptides having a positivity index of at least about 100 and a mean T cell stimulation index of at least about 4 include: LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), and LPIX-17 (SEQ ID NO:19).

In Fig. 5, the bar represents the cumulative rank of the peptide response in the group of patients tested as described in Example 2. To determine the cumulative rank, the 5 peptides with the highest S.I. in each individual were determined and assigned a numerical rank in descending order, with 5 representing the strongest response. The ranks for each peptide were then summed for the entire group of patients tested to determine the cumulative rank for the peptide. Above each bar is the mean S.I. for each peptide and the percent of positive responses (in parenthesis) with an S.I. of at least 2 to the peptide in the group of patients tested.

In order to determine precise T cell epitopes by, for example, fine mapping techniques, a peptide having T cell stimulating activity and thus comprising at least one T cell epitope as determined by T cell biology techniques is modified by addition or deletion of amino acid

residues at either the amino or carboxy terminus of the peptide and tested to determine a change in T cell reactivity to the modified peptide. Following this technique, peptides are selected and produced recombinantly or synthetically. Peptides are selected based on various factors, including the strength of the T cell response to the peptide (e.g., stimulation index), the frequency 5 of the T cell response to the peptide in a population of individuals sensitive to ryegrass pollen, and the potential cross-reactivity of the peptide with other allergens from other species of grasses as discussed earlier i.e. *Dactylis glomerata*. The physical and chemical properties of these selected peptides (e.g., solubility, stability) are examined to determine whether the peptides are suitable for use in therapeutic compositions or whether the peptides require modification as 10 described herein. The ability of the selected peptides or selected modified peptides to stimulate human T cells (e.g., induce proliferation, lymphokine secretion) or cause appropriate T cell populations to become non-responsive or have a reduced response to the protein allergen is determined.

In addition, it may be desirable to further modify peptides such as LPIX-4 (SEQ ID 15 NO:6),-5 (SEQ ID NO:7),-6 (SEQ ID NO:8),-11 (SEQ ID NO:13),-12 (SEQ ID NO:14),-16 (SEQ ID NO:18),-17 (SEQ ID NO:19)and -20 (SEQ ID NO:22) for purposes of increasing solubility or stability. Modifications to improve solubility include truncation from either the amino or carboxyl terminus of the peptide or both termini to remove hydrophilic amino acids such as Val, Ile, Leu, Phe, Tyr and Trp. Residues removed by truncation may also be replaced 20 with charged hydrophilic amino acids such as Asp, Glu, Lys and Arg or neutral hydrophilic amino acids such as Ser, Pro, Gly or Ala. Such amino acids may be of either the R or S optical configuration.

Other modifications to improve solubility include attachment of hydrophilic polymers to either the amino- or carboxy terminus of the peptides or to both. Such polymers may be 25 polyanionic, polycationic or neutral (such as polyoxyethylene).

Modifications to improve stability include deletion or replacement of Asn and Gln residues and elimination of Asn-Gly, Asp-Gly and Asp-Pro sequences.

Specific examples of modifications listed above would be removal of the N-terminal Val and C-terminal Val-His-Ala-Val from peptide LIX-12. The resulting truncated peptide could be 30 used directly or the deleted residues could be replaced by combinations of the polar amino acids Asp, Glu, Lys and Arg. Similarly, the N-terminal sequence Gly-Phe and C-terminal sequence Phe-Lys-Ile could be removed from peptide LPIX-5 (SEQ ID NO:7).

Additionally, preferred T cell epitope-containing peptides of the invention do not bind immunoglobulin E (IgE) or bind IgE to a substantially lesser extent (e.g. at least 100 fold less and more preferably at least 1000 fold less) than the protein allergen from which the peptide is derived. The major complications of standard immunotherapy are IgE-mediated responses such 5 as anaphylaxis. Immunoglobulin E is a mediator of anaphylactic reactions which result from the binding and cross-linking of antigen to IgE on mast cells or basophils and the release of mediators (e.g., histamine, serotonin, eosinophil chemotactic factors). Thus, anaphylaxis in a substantial percentage of a population of individuals sensitive to *Lol p V* could be avoided by the use in immunotherapy of a peptide or peptides which do not bind IgE in a substantial percentage 10 (e.g., at least about 75%) of a population of individuals sensitive to *Lol p V* allergen, or if the peptide binds IgE, such binding does not result in the release of mediators from mast cells or basophils. The risk of anaphylaxis could be reduced by the use in immunotherapy of a peptide or peptides which have reduced IgE binding. Moreover, peptides which have minimal IgE 15 stimulating activity are desirable for therapeutic effectiveness. Minimal IgE stimulating activity refers to IgE production that is less than the amount of IgE production and/or IL-4 production stimulated by the native *Lol p V* protein allergen. Similarly, IL-4 production can be compared, with reduced IL-4 production indicating lessened IgE stimulating activity.

If a peptide of the invention is to be used as a diagnostic reagent, it is not necessary that the peptide or protein have reduced IgE binding activity compared to the native *Lol p V* allergen. 20 IgE binding activity of peptides can be determined by, for example, using various types of enzyme linked immunosorbent assays (ELISA).

Preferred T cell epitope containing peptide of the invention, when administered to a ryegrass pollen-sensitive individual or an individual sensitive to an allergen which is immunologically related to ryegrass pollen allergen such as *Dac g I*, in a therapeutic treatment 25 regimen, is capable of modifying the allergic response of the individual to the allergen. Particularly, such preferred *Lol p V* peptides of the invention comprising at least one T cell epitope of *Lol p V* or at least two regions derived from *Lol p V*, each comprising at least one T cell epitope, when administered to an individual sensitive to ryegrass pollen are capable of modifying T cell response of the individual to the allergen and are useful as therapeutics in 30 addressing sensitivity to grasses.

A preferred isolated *Lol p V* peptide of the invention comprises at least one T cell epitope of the *Lol p V* and accordingly the peptide comprises at least approximately seven amino acid residues. For purposes of therapeutic effectiveness, preferred therapeutic compositions of the invention preferably comprise at least two T cell epitopes of *Lol p V*, and accordingly, a

preferred peptide comprises at least approximately eight amino acid residues and preferably at least fifteen amino acid residues. Additionally, therapeutic compositions comprising preferred isolated peptides of the invention preferably comprise a sufficient percentage of the T cell epitopes of the entire protein allergen (i.e. at least about 40% and more preferably about 60% of
5 the T cell reactivity to the entire protein allergen) such that a therapeutic regimen of administration of the composition to an individual sensitive to ryegrass pollen, results in T cells of the individual being tolerized to the protein allergen. Synthetically produced peptides of the invention comprising up to approximately forty-five amino acid residues in length, and most preferably up to approximately thirty amino acid residues in length are particularly desirable as
10 increases in length may result in difficulty in peptide synthesis. Peptides of the invention may also be produced recombinantly as described earlier, and it is preferable that peptides of 45 amino acids or longer be produced recombinantly.

Peptides derived from the *Lol p V* protein allergen which can be used for therapeutic purposes comprise at least one T cell epitope of *Lol p V* and comprise all or a portion of the
15 following peptides: LPIX-1 (SEQ ID NO:3), LPIX-1.1 (SEQ ID NO:3), LPIX-2 (SEQ ID NO:4), LPIX-2.1 (SEQ ID NO: 4), LPIX-3 (SEQ ID NO:5), LPIX-4 (SEQ ID NO:6) LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-7 (SEQ ID NO:9), LPIX-8 (SEQ ID NO:10), LPIX-9 (SEQ ID NO:11), LPIX-10 (SEQ ID NO:12), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-13 (SEQ ID NO:15), LPIX-14 (SEQ ID NO:16), LPIX-15 (SEQ ID NO:17),
20 LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-18 (SEQ ID NO:20), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-21 (SEQ ID NO:23), LPIX-22 (SEQ ID NO:24), LPIX-23 (SEQ ID NO:25), LPIX-24 (SEQ ID NO:26), LPIX-26 (SEQ ID NO:28), and LPIX-27 (SEQ ID NO:29) (the sequences of which are shown in Fig. 2) wherein the portion of the peptide preferably has a mean T cell stimulation index (S.I.) equivalent to, or greater than the
25 mean T cell stimulation index of the peptide from which it is derived (e.g. as shown in Fig. 5, the S.I. for LPIX-16 (SEQ ID NO:18) is shown above the bar to be 3.7, therefore any portion of LPIX-16 preferably has a mean S.I. of 3.7). Even more preferably peptides derived from the *Lol p V* protein allergen which can be used for therapeutic purposes comprise all or a portion of the following peptides: LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8),
30 LPIX-8 (SEQ ID NO:10), LPIX-9 (SEQ ID NO:11), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-23 (SEQ ID NO:25), and LPIX-26 (SEQ ID NO:28) as shown in Fig. 2. Even more preferably, peptides derived from *Lol p V* protein allergen which can be used for therapeutic purposes comprise all or a portion of the following peptides: LPIX-1 (SEQ ID

DEPARTMENT OF TRADE AND INDUSTRY
REGISTRATION NUMBER 2880

NO:3), LPIX-2 (SEQ ID NO:4), LPIX-3 (SEQ ID NO:5), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-7 (SEQ ID NO:9), LPIX-8 (SEQ ID NO:10), LPIX-9 (SEQ ID NO:11), LPIX-10 (SEQ ID NO:12), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-13 (SEQ ID NO:15), LPIX-14 (SEQ ID NO:16), LPIX-15 (SEQ ID NO:17),
5 LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-18 (SEQ ID NO:20), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-21 (SEQ ID NO:23), LPIX-22 (SEQ ID NO:24), LPIX-23 (SEQ ID NO:25), LPIX-24 (SEQ ID NO:26), LPIX-26 (SEQ ID NO:28), and LPIX-27 (SEQ ID NO:29).

One embodiment of the present invention features a peptide or portion thereof of *Lol p V* which comprises at least one T cell epitope of the protein allergen and has a formula X_n-Y-Z_m . According to the formula, Y is an amino acid sequence selected from the group consisting of:
10 LPIX-1 (SEQ ID NO:3), LPIX-1.1 (SEQ ID NO:3), LPIX-2 (SEQ ID NO:4), LPIX-2.1 (SEQ ID NO: 4), LPIX-3 (SEQ ID NO:5), LPIX-4 (SEQ ID NO:6) LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-7 (SEQ ID NO:9), LPIX-8 (SEQ ID NO:10), LPIX-9 (SEQ ID NO:11), LPIX-
15 10 (SEQ ID NO:12), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-13 (SEQ ID NO:15), LPIX-14 (SEQ ID NO:16), LPIX-15 (SEQ ID NO:17), LPIX-16 (SEQ ID NO:18),
LPIX-17 (SEQ ID NO:19), LPIX-18 (SEQ ID NO:20), LPIX-19 (SEQ ID NO:21), LPIX-20
20 (SEQ ID NO:22), LPIX-21 (SEQ ID NO:23), LPIX-22 (SEQ ID NO:24), LPIX-23 (SEQ ID NO:25), LPIX-24 (SEQ ID NO:26), LPIX-26 (SEQ ID NO:28), and LPIX-27 (SEQ ID NO:29)
(the sequences of which are shown in Fig. 2). In addition, X_n are amino acid residues contiguous to the amino terminus of Y in the amino acid sequence of the protein allergen and Z_m are amino acid residues contiguous to the carboxy terminus of Y in the amino acid sequence of the protein allergen. In the formula, n is 0-30 and m is 0-30. Preferably, the peptide or portion thereof has a mean T cell stimulation index equivalent to greater than the mean T cell stimulation index of Y
25 as shown in Fig. 4. Preferably, amino acids comprising the amino terminus of X and the carboxy terminus of Z are selected from charged amino acids, i.e., arginine (R), lysine (K), histidine (H), glutamic acid (E) or aspartic acid (D); amino acids with reactive side chains, e.g., cysteine (C), asparagine (N) or glutamine (Q); or amino acids with sterically small side chains, e.g., alanine (A) or glycine (G). Preferably n and m are 0-5; most preferably n + m is less than 10.

Another embodiment of the present invention provides peptides comprising at least two regions, each region comprising at least one T cell epitope of *Lol p V* and accordingly each region comprises at least approximately seven amino acid residues. These peptides comprising at least two regions can comprise up to 100 or more amino acid residues but preferably comprise at least about 14, even more preferably at least about 20, and most preferably at least about 30

amino acid residues of the *Lol p V* allergen. If desired, the amino acid sequences of the regions can be produced and joined by a linker to increase sensitivity to processing by antigen-presenting cells. Such linker can be any non-epitope amino acid sequence or other appropriate linking or joining agent. To obtain preferred peptides comprising at least two regions, each comprising at 5 least one T cell epitope, the regions are arranged in the same or a different configuration from a naturally-occurring configuration of the regions in the allergen. For example, the regions containing T cell epitope(s) can be arranged in a noncontiguous configuration and can preferably be derived from the same protein allergen. Noncontiguous is defined as an arrangement of regions containing T cell epitope(s) which is different than that of the native amino-acid sequence 10 of the protein allergen from which the regions are derived. Furthermore, the noncontiguous regions containing T cell epitopes can be arranged in a nonsequential order (e.g., in an order different from the order of the amino acids of the native protein allergen from which the region containing T cell epitope(s) are derived in which amino acids are arranged from an amino terminus to a carboxy terminus). A peptide of the invention can comprise at least 15%, at least 15, 30%, at least 50% or up to 100% of the T cell epitopes of *Lol p V* but does not comprise the entire amino acid sequence of *Lol p V*.

The individual peptide regions can be produced and tested to determine which regions bind immunoglobulin E specific for *Lol p V* and which of such regions would cause the release of mediators (e.g., histamine) from mast cells or basophils. Those peptide regions found to bind 20 immunoglobulin E and to cause the release of mediators from mast cells or basophils in greater than approximately 10-15% of the allergic sera tested are preferably not included in the peptide regions arranged to form preferred peptides of the invention.

Examples of preferred peptide regions which do not appear to bind to IgE in preliminary IgE binding data studies (Example 3) include the amino acid sequences of such regions being 25 shown in Fig. 2 (SEQ ID NO:3-29), or portions of said regions comprising at least one T cell epitope.

Preferred peptides comprise various combinations of two or more of the above-discussed preferred regions, or a portion thereof. Preferred peptides comprising a combination of two or more regions (each region having an amino acid sequence as shown in Fig. 2), include the 30 following:

LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);
LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);

LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-17 (SEQ ID NO:19) and LPIX-20 (SEQ ID NO:22);

LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8) and LPIX-20 (SEQ ID NO:22);

5 LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19) and LPIX-20 (SEQ ID NO:22);

LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-8 (SEQ ID NO:10), LPIX-9 (SEQ ID NO:11), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-10 16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-23 (SEQ ID NO:25) and LPIX-26 (SEQ ID NO:28);

LPIX-4 (SEQ ID NO:6), LPIX-11 (SEQ ID NO: 13), LPIX-16 (SEQ ID NO:18), and LPIX-20 (SEQ ID NO:22);

LPIX-4 (SEQ ID NO:6), LPIX-11 (SEQ ID NO: 13), LPIX-17 (SEQ ID NO:19), and LPIX-20 15 (SEQ ID NO:22);

LPIX-4 (SEQ ID NO:6), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);

LPIX-5 (SEQ ID NO:7), LPIX-11 (SEQ ID NO: 13), LPIX-16 (SEQ ID NO:18), and LPIX-20 (SEQ ID NO:22);

20 LPIX-5 (SEQ ID NO:7), LPIX-11 (SEQ ID NO: 13), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);

LPIX-5 (SEQ ID NO:7), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);

LPIX-11 (SEQ ID NO: 13), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), and LPIX-20 25 (SEQ ID NO:22);

LPIX-4 (SEQ ID NO:6), LPIX-11 (SEQ ID NO: 13), and LPIX-20 (SEQ ID NO:22);

LPIX-4 (SEQ ID NO:6), LPIX-16 (SEQ ID NO:18), and LPIX-20 (SEQ ID NO:22);

LPIX-4 (SEQ ID NO:6), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);

LPIX-5 (SEQ ID NO:7), LPIX-11 (SEQ ID NO: 13), and LPIX-20 (SEQ ID NO:22);

30 LPIX-5 (SEQ ID NO:7), LPIX-16 (SEQ ID NO:18), and LPIX-20 (SEQ ID NO:22);

LPIX-11 (SEQ ID NO: 13), LPIX-16 (SEQ ID NO:18), and LPIX-20 (SEQ ID NO:22);

LPIX-11 (SEQ ID NO: 13), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);

LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22).

In yet another aspect of the present invention, a composition is provided comprising at least two peptides (e.g., a physical mixture of at least two peptides), each comprising at least one T cell epitope of *Lol p V*. Such compositions can be in the form of a composition additionally with a pharmaceutically acceptable carrier or diluent for therapeutic uses, or with conventional non-pharmaceutical excipients for reagent use. When used therapeutically, an effective amount of one or more of such compositions can be administered simultaneously or sequentially to an individual sensitive to ryegrass pollen.

In another aspect of the invention, combinations of *Lol p V* peptides are provided which can be administered simultaneously or sequentially. Such combinations may comprise therapeutic compositions comprising only one peptide, or more peptides if desired. Such compositions may be used simultaneously or sequentially in preferred combinations.

Preferred compositions and preferred combinations of *Lol p V* peptides which can be administered or otherwise used simultaneously or sequentially (comprising peptides having amino acid sequences shown in Fig. 2) include the following combinations:

- 15 LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);
LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);
LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-17 (SEQ ID NO:19) and LPIX-20 (SEQ ID NO:22);
LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8) and LPIX-20 (SEQ ID NO:22);
LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19) and
25 LPIX-20 (SEQ ID NO:22);
LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-8 (SEQ ID NO:10), LPIX-9 (SEQ ID NO:11), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-23 (SEQ ID NO:25) and LPIX-26 (SEQ ID NO:28);
30 LPIX-4 (SEQ ID NO:6), LPIX-11 (SEQ ID NO: 13), LPIX-16 (SEQ ID NO:18), and LPIX-20 (SEQ ID NO:22);
LPIX-4 (SEQ ID NO:6), LPIX-11 (SEQ ID NO: 13), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);

DEPARTMENT OF DOCUMENTS

LPIX-4 (SEQ ID NO:6), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);

LPIX-5 (SEQ ID NO:7), LPIX-11 (SEQ ID NO: 13), LPIX-16 (SEQ ID NO:18), and LPIX-20 (SEQ ID NO:22);

5 LPIX-5 (SEQ ID NO:7), LPIX-11 (SEQ ID NO: 13), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);

LPIX-5 (SEQ ID NO:7), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);

LPIX-11 (SEQ ID NO: 13), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), and LPIX-20

10 (SEQ ID NO:22);

LPIX-4 (SEQ ID NO:6), LPIX-11 (SEQ ID NO: 13), and LPIX-20 (SEQ ID NO:22);

LPIX-4 (SEQ ID NO:6), LPIX-16 (SEQ ID NO:18), and LPIX-20 (SEQ ID NO:22);

LPIX-4 (SEQ ID NO:6), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);

LPIX-5 (SEQ ID NO:7), LPIX-11 (SEQ ID NO: 13), and LPIX-20 (SEQ ID NO:22);

15 LPIX-5 (SEQ ID NO:7), LPIX-16 (SEQ ID NO:18), and LPIX-20 (SEQ ID NO:22);

LPIX-11 (SEQ ID NO: 13), LPIX-16 (SEQ ID NO:18), and LPIX-20 (SEQ ID NO:22);

LPIX-11 (SEQ ID NO: 13), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);

LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22).

In another aspect of the present invention, a therapeutic composition is provided comprising at least two peptides (e.g. a physical mixture of at least two peptides, each peptide comprising at least one epitope) wherein at least one peptide, comprises an amino acid sequence or portion thereof derived from *Lol p V* selected from the following group: LPIX-1 (SEQ ID NO:3), LPIX-2 (SEQ ID NO:4), LPIX-3 (SEQ ID NO:5), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-7 (SEQ ID NO:9), LPIX-8 (SEQ ID NO:10), LPIX-9 (SEQ ID NO:11), LPIX-10 (SEQ ID NO:12), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-13 (SEQ ID NO:15), LPIX-14 (SEQ ID NO:16), LPIX-15 (SEQ ID NO:17), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-18 (SEQ ID NO:20), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-21 (SEQ ID NO:23), LPIX-22 (SEQ ID NO:24), LPIX-23 (SEQ ID NO:25), LPIX-24 (SEQ ID NO:26), LPIX-26 (SEQ ID NO:28), and 30 LPIX-27 (SEQ ID NO:29) (as shown in Fig. 2), and wherein at least one peptide comprises an amino acid sequence or portion thereof derived from *Lol p I* selected from the following group: LPI-1 (SEQ ID NO:30), LPI-1.1 (SEQ ID NO:31), LPI-2 (SEQ ID NO:32), LPI-3 (SEQ ID NO:55), LPI-4 (SEQ ID NO:33), LPI-4.1 (SEQ ID NO:34), LPI-5 (SEQ ID NO:35), LPI-6 (SEQ ID NO:36), LPI-7 (SEQ ID NO:37), LPI-8 (SEQ ID NO:38), LPI-9 (SEQ ID NO:39), LPI-10

(SEQ ID NO:40), LPI-11 (SEQ ID NO:41), LPI-12 (SEQ ID NO:42), LPI-13 (SEQ ID NO:43), LPI-14 (SEQ ID NO:44), LPI-15 (SEQ ID NO:45), LPI-16 (SEQ ID NO:46), LPI-16.1 (SEQ ID NO:47), LPI-17 (SEQ ID NO:48), LPI-18 (SEQ ID NO:49), LPI-19 (SEQ ID NO:50), LPI-20 (SEQ ID NO:56), LPI-21 (SEQ ID NO:51), LPI-22 (SEQ ID NO:52), and LPI-23 (SEQ ID NO:53). (as shown in Fig. 3). The isolation and cloning of the clones encoding *Lol p* I as well as the synthesis of the various *Lol p* I peptides shown in Fig. 3, along with human T cell studies using *Lol p* I and using various peptides derived from *Lol p* I are described in PCT/US94/02537, which is hereby incorporated by reference in its entirety.

Preferably, a therapeutic composition comprises at least five, six, seven, or eight peptides wherein at least three or four peptides are derived from *Lol p* V and are selected from the following group: LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-11 (SEQ ID NO:13), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22), and at least two, three or four peptides are derived from *Lol p* I and selected from the following group: LPI-16 (SEQ ID NO:46), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), and LPI-23 (SEQ ID NO:53); for example, a preferred therapeutic composition comprises at least two peptides of *Lol p* I and three peptides of *Lol p* V, or three peptides from *Lol p* I and three peptides from *Lol p* V, or three peptides from *Lol p* I and four peptides from *Lol p* V, or four peptides from *Lol p* I and four peptides from *Lol p* V, or four peptides from *Lol p* I and three peptides from *Lol p* V.

In another aspect of the present invention a method is provided comprising administering a combination of peptides or portions thereof derived from *Lol p* V and *Lol p* I which can be administered simultaneously or sequentially; each of such peptides can be in the form of a therapeutic composition with a pharmaceutically acceptable carrier or diluent. Examples of preferred compositions and preferred combinations comprising *Lol p* V and *Lol p* I peptides or portions thereof, which can be administered simultaneously or sequentially comprise the following combinations:

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-10 (SEQ ID NO:40), LPI-11 (SEQ ID NO:41), LPI-15 (SEQ ID NO:45), LPI-22 (SEQ ID NO:52), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-8 (SEQ ID NO:10), LPIX-9 (SEQ ID NO:11), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-23 (SEQ ID NO:25), LPIX-26 (SEQ ID NO:28);
LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20, LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-10 (SEQ ID NO:40), LPI-11 (SEQ ID NO:41),

LPI-15 (SEQ ID NO:45), LPI-22 (SEQ ID NO:52), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-8 (SEQ ID NO:10), LPIX-9 (SEQ ID NO:11), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-23 (SEQ ID NO:25),
5 LPIX-26 (SEQ ID NO:28), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-9 (SEQ ID NO:11), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

10 LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-10 (SEQ ID NO:40), LPI-11 (SEQ ID NO:41), LPI-15 (SEQ ID NO:45), LPI-22 (SEQ ID NO:52), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-9 (SEQ ID NO:11), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21),
15 LPIX-20 (SEQ ID NO:22), LPIX-23 (SEQ ID NO:25);-

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-10 (SEQ ID NO:40), LPI-11 (SEQ ID NO:41), LPI-15 (SEQ ID NO:45), LPI-22 (SEQ ID NO:52), LPIX-4 (SEQ ID NO:6),
20 LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-10 (SEQ ID NO:40), LPI-11 (SEQ ID NO:41), LPI-15 (SEQ ID NO:45), LPI-22 (SEQ ID NO:52), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);
25

30 LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-10 (SEQ ID NO:40), LPI-11 (SEQ ID NO:41), LPI-15 (SEQ ID NO:45), LPI-22 (SEQ ID NO:52);

2025 RELEASE UNDER E.O. 14176

(SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-8 (SEQ ID NO:10), LPIX-9 (SEQ ID NO:11),
LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17
(SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22); LPIX-23 (SEQ ID
NO:25), LPIX-26 (SEQ ID NO:28);

5 LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID
NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPIX-4 (SEQ ID NO:6), LPIX-5
(SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-9 (SEQ ID NO:11), LPIX-11 (SEQ ID NO:13),
LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19
10 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID
NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPIX-4 (SEQ ID NO:6), LPIX-5
(SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-9 (SEQ ID NO:11), LPIX-12 (SEQ ID NO:14),
15 LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20
(SEQ ID NO:22), LPIX-23 (SEQ ID NO:25);

20 LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID
NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPIX-4 (SEQ ID NO:6), LPIX-5
(SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18),
LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

25 LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID
NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPIX-4 (SEQ ID NO:6), LPIX-5
(SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19),
LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

30 LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID
NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPIX-4 (SEQ ID NO:6), LPIX-5
(SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19),
LPIX-20 (SEQ ID NO:22);

35 LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID
NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-22 (SEQ. ID NO:52), LPIX-4
(SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-8 (SEQ. ID NO:10),
LPIX-9 (SEQ. ID NO:11), LPIX-11 (SEQ. ID NO:13), LPIX-12 (SEQ. ID NO:14), LPIX-16
(SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ. ID NO:21), LPIX-20 (SEQ ID
NO:22), LPIX-23 (SEQ. ID NO:25), LPIX-26 (SEQ. ID NO:28);

40 LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID
NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-22 (SEQ ID NO:52), LPIX-4

2025 RELEASE UNDER E.O. 14176

(SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-8 (SEQ ID NO:10),
LPIX-9 (SEQ ID NO:11), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ
ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

5 LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID
NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-22 (SEQ ID NO:52), LPIX-4
(SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-9 (SEQ ID NO:11),
LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19
(SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-23 (SEQ ID NO:25);

10 LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID
NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-22 (SEQ ID NO:52), LPIX-4
(SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-12 (SEQ ID NO:14),
LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20
(SEQ ID NO:22);

15 LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID
NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-22 (SEQ ID NO:52), LPIX-4
(SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-16 (SEQ ID NO:18),
20 LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

25 LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID
NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-22 (SEQ ID NO:52), LPIX-4
(SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-16 (SEQ ID NO:18),
LPIX-17 (SEQ ID NO:19), LPIX-20 (SEQ ID NO:22);

30 LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID
NO:53), LPI-3 (SEQ ID NO:55), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ
ID NO:8), LPIX-8 (SEQ ID NO:10), LPIX-9 (SEQ ID NO:11), LPIX-11 (SEQ ID NO:13),
LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19
(SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-23 (SEQ ID NO:25), LPIX-26 (SEQ ID
NO:28);

35 LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID
NO:53), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-9
(SEQ ID NO:11), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID
NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

40 LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID
NO:53), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-9

(SEQ ID NO:11), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-23 (SEQ ID NO:25);

5 LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

10 LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22); and--.

15 LPI-16.1, LPI-18, LPI-20, LPI-23, LPIX-4, LPIX-5, LPIX-6, LPIX-16, LPIX-17, LPIX-20' with
--LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-20 (SEQ ID NO:22).

20 In addition, a composition is provided comprising at least two *Lol p I* peptides (e.g. a physical mixture of at least two peptides), each comprising at least one T cell epitope of *Lol p I*. Such compositions can be administered in the form of a therapeutic composition with a pharmaceutically acceptable carrier or diluent to treat ryegrass sensitivity and particularly, sensitivity to *Lol p I* protein allergen. Preferred compositions and preferred combinations of *Lol p I* peptides which can be administered simultaneously or sequentially (comprising peptides 25 having the amino acid sequences shown in Fig. 3 include the following combinations:

LPI-16 (SEQ ID NO:46), and LPI-20 (SEQ ID NO:56);

LPI-18 (SEQ ID NO:49), and LPI-20 (SEQ ID NO:56);

LPI-20 (SEQ ID NO:56), and LPI-23 (SEQ ID NO:53);

30 LPI-16 (SEQ ID NO:46), LPI-18 (SEQ ID NO:49), and LPI-20 (SEQ ID NO:56);

LPI-16 (SEQ ID NO:46), LPI-20 (SEQ ID NO:56), and LPI-23 (SEQ ID NO:53);

LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), and LPI-23 (SEQ ID NO:53);

LPI-16 (SEQ ID NO:46), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), and LPI-23 (SEQ ID NO:53).

35

Any of the compositions described herein are useful in the manufacture of a medicament for treating sensitivity to ryegrass pollen allergen or an immunologically cross reactive allergen in an individual.

The present invention is further illustrated by the following non-limiting Figures and Examples.

EXAMPLE I

5

Purification of Native *Lol p* V from ryegrass pollen

A. Production and purification of monoclonal antibody (mAb) 1B9.

Balb/c mice were immunized with crude *Dactylis glomerata* (orchard grass/cockfoot grass) 10 pollen extract and antibody secreting clones were generated as described (Walsh *et al.*, *Int. Arch. Allergy Appl. Immunol.*, 1990, 91: 419-425). MAb 1B9 hybridoma clone which cross-reacts to *Lol p* V was obtained from Dr. Walker (Univ. Birmingham, Wolfson Research Lab, Birmingham, UK). Ascitic fluid generated from Balb/c mice was produced by contract (Babco, Richmond, CA). The antibodies were purified from ascites fluid by $(\text{NH}_4)_2\text{SO}_4$ precipitation (50% saturation). The pellet was resuspended 15 10mM phosphate buffer, pH 7.5 and dialyzed against the same buffer at 4°C overnight and then fractionated by ion-exchange chromatography on FPLC Q-Sepharose (Pharmacia, Piscataway, NJ) using linear gradient 0-0.5 M NaCl. IgG was eluted between 0.15-0.2 M NaCl concentration.

20

B. Preparation of 1B9 immunoaffinity column

25

Purified 1B9 was coupled to Affigel-10 (Biorad, Richmond, CA) using 3-4 mg protein/mL of according to manufacturer's instructions. In brief, PFLC Q-Sepharose purified mAb 1B9 was dialyzed against 0.1M MOPS buffer, pH 7.5 with two to three changes overnight at 4°C. The Affigel-10 resin was washed with deionized cold H₂O in a scintered glass funnel. The washed resin was mixed with 1B9 antibody for four hours at 4°C, followed by an one-hour blocking step with 1 M ethanolamine, pH 8.0. Resin was packed into a column, washed with PBS and then stored in PBS + 0.05% sodium azide.

30

C. Affinity purification of *Lol p* V from ryegrass pollen

100g defatted ryegrass pollen (purchased from Greer Laboratories, Lenoir, NC) was extracted 1 liter extraction buffer containing 0.05 M phosphate buffer, pH 7.2, 0.15 M NaCl, phenyl methyl sulfonyl fluoride (170 µg/mL), leupeptin (1 µg/mL), pepstatin (1 µg/mL) and soybean trypsin inhibitor (1 µg/mL).

The pollen was extracted by stirring the solution overnight at 4°C, followed by centrifugation 12,000 x g for 100 minutes. The insoluble materials were re-extracted in 0.5-1.0L extraction buffer a then the supernatants were combined and depigmented by batch absorption onto 100 mL DE-52 cellulose (Whatman, Maidstone, England) equilibrated with 0.05 M phosphate buffer + 0.3 M NaCl,
5 7.2.

The unbound materials were loaded onto the 1B9-Affigel-10 column at a flow rate of 0.5ml/ The column was then washed extensively with PBS, PBS + 0.5 M NaCl and once again with PBS bef elution of the *Lol p* V allergens with 0.1 M glycine, pH 2.7. Fractions were neutralized with 1 M Tri
10 pH 11.0 immediately. These affinity-purified materials were used in IgE studies and T cell epitope mapping.

Physicochemical properties of affinity-purified *Lol p* V

The 1B9 affinity-purified material was analyzed by SDS-PAGE. As shown in Fig. 15, *Lol p* exists as multiple bands with molecular weight ranged from 29,000 - 22,000. All these components
15 were reactive with 1B9 by Western blotting analysis (data not shown). These components were electroblotted onto ProBlott membrane (Applied Biosystems, Foster City, CA), stained by Coomassi blue and the three major bands were excised and sequenced on a Beckman LF-3000 sequencer (Beckman Instruments, Carlsbad, CA). N-terminal amino acid sequence of the three bands are show Table I. The sequencing data shows that the middle and lower molecular weight bands represent N-
20 terminal cleavage products of the higher molecular weight component. The N-terminus sequence wa identical to the cloned *Lol p* V (12R) (see PCT application publication number WO93/04174). The 5 proline residues at the N-terminus were found to be all hydroxyprolines, which seemed to be commo Group V allergens from Northern grasses (Matthiesen, F. et al., 1991, *Clin. Exp. Allergy*, **21**:297-307 We also determined the 1B9-affinity purified material by amino acid analysis (Table 2) and the data
25 were very similar to the *Lol p* V and other group V allergens from Northern grasses reported by Klys et al., (*Clin. Experimental Allergy*, 1992, **22**:491-497). Furthermore, Western blot analysis using specific anti-group I mAb (data not shown) demonstrated Group I proteins could not be detected in th preparations. Thus, taken together these data suggest that the 1B9-affinity purified preparations contained only Group V allergens.

Table 1

5

N-terminal amino acid sequence and cleavage site of *Lol p V* allergen

	amino acid #	1	↓	11	↓	—
10	Lol p V	A D A G Y T P'	A A A A A T P'	A T P'	A A T P'	
		21		31		
		A A A G G K A T T D E Q K				

15

P' represents hydroxyproline

20

The N-terminal sequence was determined from the three major bands electroblotted onto ProBlott membrane. The upper band starts with amino acid 1 whereas the middle and the lower bands start at amino acid 9 and 18, respectively. The arrows indicate the cleavage sites.

Table 2 : Amino acid composition of Group V allergens

Amino acid	<i>Phl p</i> V ^a	<i>Lol p</i> V ^a	Mole %		
			expt 1	<i>Lol p</i> V ^b expt 2	expt 3
Asx	5.4	6.3	5.3	6.7	7.5
Thr	7.6	8.6	7.4	8.7	9.2
Ser	5.1	2.0	3.3	2.3	2.7
Glx	10.2	9.8	7.4	8.8	8.9
Gly	6.4	4.0	7.2	5.2	4.8
Ala	25.7	29.0	27.7	31.3	31.7
Cys	0.0	1.0	---	---	---
Val	6.6	6.4	5.5	5.5	6.4
Met	0.7	0.3	0.5	0.3	0.8
Ile	3.6	3.4	3.5	2.9	3.1
Leu	4.7	5.9	6.5	5.0	5.3
Tyr	3.5	3.0	2.9	2.5	1.7
Phe	4.1	5.0	4.8	4.0	4.5
His	0.8	0.3	---	0.2	0.5
Lys	8.8	9.8	11.0	9.2	6.0
Arg	1.0	0.4	0.6	0.4	0.8
Pro	4.5	4.9	5.4 ^c	4.7 ^c	3.7 ^c
Hyp	1.4	N.R.	1.5 ^c	1.8 ^c	1.7 ^c

N.R. (Not reported)

^a values reported by Klysner, S. et al. Clin. Exp. Allergy (1992) 22: 491-497.

^b the amino acid composition was determined from mAb 1B9-affinity purified materials and values obtained from three experiments are presented.

^c the content of proline and hydroxyproline was determined by peak height since the hydroxyproline peak was very broad due to a contaminant which eluted at the trailing edge of the hydroxyproline peak. All the other amino acids determined by peak areas.

Example 2 - Human T Cell Studies with *Lol p* V

Synthesis of Overlapping Peptides

The amino acid sequence of *Lol p* V was deduced from the cDNA sequence of clone 12R (SEQ ID NO:2) ATCC number 69475 as shown in Fig. 1. The details of the isolation and cloning of clone 12R encoding *Lol p* V (described as *Lol p* Ib.1) are given in PCT application publication number WO93/04174 incorporated herein by reference in its entirety. One example of expression of recombinantly produced *Lol p* V encoded by clone 12R is given in Example 4, to follow.

Ryegrass *Lol p* V overlapping peptides were synthesized using standard Fmoc/tBoc synthetic chemistry and purified by Reverse Phase HPLC. Fig. 2 shows *Lol p* V peptides used in these studies. The peptide names are consistent throughout.

T Cell Responses to Ryegrass Antigen Peptides

Peripheral blood mononuclear cells (PBMC) were purified by lymphocyte separation medium (LSM) centrifugation of 60 ml of heparinized blood from grass-allergic patients who exhibited clinical symptoms of seasonal rhinitis and were skin test positive for grass. Long-term T cell lines were established by stimulation of 2×10^6 PBL/ml in bulk cultures of complete medium (IRPMI-164), 2 mM L-glutamine, 100 U/ml penicillin/streptomycin, 5×10^{-5} M 2-mercaptoethanol, and 10 mM HEPES, supplemented with 5% heat-inactivated human AB serum, with 10 μ g/ml of affinity purified native *Lol p* V for 6 days at 37°C in a humidified 5% CO₂ incubator to select for *Lol p* V reactive T Cells. This amount of priming antigen was determined to be optimal for the activation of T cells from most grass-allergic patients. Viable cells were purified by LSM centrifugation and cultured in complete medium, supplemented with 5 units recombinant human IL-2/ml and 5 units recombinant human IL-4/ml for up to 3 weeks until the desired cell number were achieved. The cells were allowed to rest for 4-6 days.

The ability of the T cells to proliferate to selected peptides, recombinant *Lol p* I (r*Lol p* I), purified native *Lol p* V, purified r*Lol p* V, or recombinant *Fel d* I (r*Fel d* I) (chain I), or tetanus toxoid (TT) was then assessed. For assay, 2×10^4 rested cells were restimulated in the presence of 2×10^4 autologous Epstein-Barr virus (EBV)-transformed B cells (prepared as described below) or 5×10^4 irradiated PBL with 2-50 mg/ml of r*Lol p* I, purified native *Lol p* V, r*Fel d* I (Chain I), or r*Lol p* I, in a volume of 200 ml complete medium in duplicate wells in 96-well round-bottom plates for three days. Each well then received 1 mCi tritiated thymidine for 16-20 hours. The counts incorporated were collected onto glass fiber filter mats and processed for

liquid scintillation counting. The varying antigen dose in assays with r*Lol p* V, purified native *Lol p* V, and recombinant *Lol p* I and antigenic peptides synthesized as described above were determined. The titrations were used to optimize the dose of peptides in T cell assays. The maximum response in a titration of each peptide is expressed as the stimulation index (S.I.). The 5 S.I. is the counts per minute (CPM) incorporated by cells in response to peptide, divided by the CPM incorporated by cells in medium only. An S.I. value equal to or greater than 2 times the background level is considered "positive" and indicates that the peptide contains a T cell epitope. The positive results were used in calculating mean stimulation indices for each peptide for the group of patients tested. The results (not shown) demonstrate that one patient responds well to 10 recombinant *Lol p* V and purified native *Lol p* V, as well as to *Lol p* V peptides but not to r*Fel d* I (Chain I) or TT. This indicated that *Lol p* V T cell epitopes are recognized by T cells from this particular allergic patient and that r*Lol p* V contains such T cell epitopes.

The above procedure was followed with a total of 19 patients. Individual patient results were used in calculating the mean S.I. for each peptide if the patient responded to the purified 15 native *Lol p* V protein at an S.I. of 2.0 or greater and the patient responded to at least one peptide derived from purified native *Lol p* I at an S.I. of 2.0 or greater. A summary of positive experiments from 19 patients is shown in Fig. 4. The numbers above each bar report the mean S.I. for that peptide. The numbers enclosed in the parentheses denote percentage of patients responding to that particular peptide. The bar represents the positivity index for each peptide (% 20 of patients responding multiplied by mean S.I.).

Fig. 5 shows the ranked sum for each peptide derived from the same data as described above. The bar represents the cumulative rank of the peptide response in the group of the 19 patients tested. To determine the cumulative rank, the 5 peptides with the highest S.I. in each individual are determined and assigned a numerical rank in descending order, with 5 representing 25 the strongest response. The ranks for each peptide were then summed for the entire group of patients to determine the cumulative rank for the peptide. Above each bar is the mean S.I. and percent of positive responses (in parenthesis) with an S.I. of at least 2 to the peptide in the group of 19 patients tested. Given the percent positive and the mean T cell stimulation index, the positivity index (P.I.) for each peptide can be calculated by multiplying the two numbers. Fig. 5 30 shows that LPIX-20 has the highest ranked sum of the peptides in this study.

Example 3

Lol p V as a Major Ryegrass Pollen Allergen

A) ELISA Analysis

To examine the importance of *Lol p* V, both direct and competition ELISA assays were performed. In the direct ELISA, 100 μ l of 10 μ g/ml of antigen in Phosphate Buffered Saline, pH 7.4 (PBS) was used to coat Immulon II (Dynatech, Chantilly, VA) 96 well plates for 4 hours at room temperature (RT) or overnight (O/N) at 4°C. In between each step the plates were washed 3X with PBS-T. The excess coating antigen(s) was removed and the wells blocked with 300 μ l/well 0.5% gelatin + 1mg/ml PVP in PBS for 1 hour at RT. Serially diluted patient plasma or the diluent PBS + 0.05% Tween²⁰ was incubated in at 100 μ l/well in duplicate wells overnight at 4°C. Unbound antibody was removed, and the wells incubated with 100 μ l/well of 2nd Ab (1:1000, biotinylated goat anti-human IgE, KPL Inc., Gaithersburg, MD) for 1 hour at RT. This solution was removed and streptavidin-horse radish peroxidase (HRPO) (1:10000) was added at 100 μ l/well (SBA Inc., Birmingham, AL) and incubated for 1 hr at RT. 3, 3', 5, 5'-tetramethylbenzidine (TMB) Substrate (KPL, Gaithersburg, MD) was freshly mixed and added at 100 μ l/well and the color allowed to develop for 1-5 minutes. The reaction was stopped by the addition of 100 μ l/well 1M phosphoric acid. Plates were read on a MR7000 plate reader (Dynatech, Chantilly, VA) with a 450nm filter. The absorbance levels of duplicate wells were averaged. The results were graphed as absorbance vs. dilution. The competition ELISA were carried out using the same protocol with the following changes: a single dilution of patient plasma (or pooled human plasma (PHP)) was used as the source of IgE; serially diluted antigen was mixed with the plasma and allowed to incubate O/N at 4°C. This plasma was then incubated on duplicate wells. The results are plotted as the absorbance vs. the log of the concentration of competing antigen.

25

For the direct ELISA, wells were coated with either soluble pollen extract (SPE) of ryegrass pollen or r*Lol p* V (purified native *Lol p* V may have a small amount of *Lol p* I; use of recombinant material assures that the IgE binding is only to *Lol p* V) and human IgE antibody binding to these antigens was analyzed. PHP, consisting of an equal volume of plasma from 20 patients with a ryegrass prick test score of 3+ or greater (PHP-A), or PHP consisting of equal aliquots of plasma from 40 grass skin test reactive patients with high IgE binding as measured by direct ELISA (PHP-B), or plasma from individual patients were compared in this assay. The results of binding reactivity with PHP-A (Fig. 6), PHP-B (Fig. 7), four individual patients on

ryegrass pollen SPE (Fig. 8), and purified r*Lol p* V (Fig. 9) to either SPE or r*Lol p* V, indicate that there is high IgE binding to both the pollen extract and the recombinant protein.

In the competition assay, ELISA wells were coated with ryegrass pollen SPE and then allergic patient IgE binding was measured in the presence of competing ryegrass pollen SPE, purified native *Lol p* V, or r*Lol p* V. The source of allergic IgE in this assay was PHP-A (Figure 10) or individual patient plasma (Figure 11). The competition assays confirm that a significant portion of IgE against *Lol p* SPE is specific for *Lol p* V.

10 B) Histamine Release Analysis

A histamine release assay was performed on one ryegrass allergic individual, using *Lol p* SPE and r*Lol p* V as the added antigens. This assay is a measure of IgE reactivity through human basophil mediator release, and it is based on the detection of an acylated derivative of histamine using a specific monoclonal antibody (Morel, A.M. and Delaage, M.A.; 1988, J. Allergy Clin. Immunol. 82: 646-654). The reagents for this radioimmunoassay are sold as a kit by Amac Inc. (Westbrook, ME). Whole heparinized blood drawn from a grass allergic individual and then 200 μ l aliquots were mixed with an equal amount of the grass antigens SPE and r*Lol p* V at various concentrations or the diluent, PACM buffer (25mM PIPES, 100mM NaCl, 5mM KCL, 4mM CaCl₂, 1mM MgCl₂, 0.003% HSA, pH7.3) in 1.5ml polypropylene. The release reactions were carried out at 37°C for 30 minutes. After this incubation, the samples were centrifuged at 1500 RPM for 3 minutes and the supernatants removed. For the total histamine release, 0.1ml of blood was added to 0.9ml of PACM buffer, vortexed, and then boiled for 3 minutes. The samples were spun at 13000 RPM and the supernatant removed for analysis. Duplicate samples were used to measure total release. All of the supernatants are diluted 1:4 in acylation buffer and the remainder of the assay is performed according to the manufacturer's instructions. The results of this assay, shown in Figure 12, demonstrate strong histamine release over a wide concentration range for both the extract and the recombinant protein.

30 C) Reactivity to *Lol p* V peptides

Direct ELISA was performed to assess the IgE reactivity to *Lol p* V peptides. In this assay ELISA plates were coated with the set of synthetic *Lol p* V peptides (as shown in Fig. 2) and r*Lol p* V protein. Human IgE binding of PHP-B was incubated on the wells and the resulting

binding analyzed. As evidenced in Fig. 13a and Fig. 13b there is no significant binding detected to any of the *Lol p* V peptides in this preliminary assay although there is very high IgE binding to *Lol p* V protein.

5 D) *Lol p* I and *Lol p* V constitute the major allergens of ryegrass pollen

A separate competition ELISA was done to show that *Lol p* I and *Lol p* V together constitute the major IgE binding proteins of ryegrass pollen SPE. In this assay (Fig 14), PHP-B⁺ was used to examine the ability of a mixture of native purified *Lol p* I and *Lol p* V or a mixture of 10 r*Lol p* I and r*Lol p* V to compete for IgE binding to ryegrass pollen SPE. The mixture of purified native proteins competes to background level the IgE binding to ryegrass pollen SPE. The mixture of r*Lol p* I and r*Lol p* V is also able to substantially reduce the amount of IgE available 15 to bind to the SPE coating the plate. The majority of human IgE directed against all of the ryegrass pollen proteins was bound up by the mix of just two proteins (*Lol p* I and *Lol p* V) found in the complex mix of ryegrass pollen SPE proteins. This data implies that these two proteins are major allergens of ryegrass pollen.

Example 4

20 **Expression of *Lol p* V**

Expression of *Lol p* V was performed as follows. The λgtII clone 12R was digested with EcoRI. The insert encoding *Lol p* V was ligated into pGEX. A pGEX vector containing *Lol p* V (clone 12R) was digested with EcoR1. The *Lol p* V insert (containing the nucleotide sequence shown in Fig. 1) was isolated by electrophoresis of this digest through a 1% SeaPlaque low melt 25 agarose gel. The insert was then ligated into EcoR1 digested expression vector pET-11d (Novagen, Madison, WI; Jameel et al. (1990) *J. Virol.* **64**:3963-3966) modified to contain a sequence encoding 6 histidines (His 6) immediately 3' of the ATG initiation codon followed by a unique EcoR I endonuclease restriction site. A second EcoR I endonuclease restriction site in the vector, along with neighboring *Cla* I and *Hind* III endonuclease restriction sites, had previously 30 been removed by digestion with EcoR I and *Hind* III, blunting and religation. The histidine (His6) sequence was added for affinity purification of the recombinant protein (r*Lol p* V) on a Ni²⁺ chelating column (Hochuli et al. (1987) *J. Chromatog.* **411**:177-184; Hochuli et al. (1988) *Bio/Tech.* **6**:1321-1325.). A recombinant clone was used to transform *Escherichia coli* strain BL21-DE3 which harbors a plasmid that has an isopropyl-β-D-thiogalactopyranoside (IPTG)-35 inducible promoter preceding the gene encoding T7 polymerase. Induction with IPTG leads to

high levels of T7 polymerase expression, which is necessary for expression of the recombinant protein in pET-11d, which has a T7 promoter. The pET-11d containing the *Lol p* V (clone 12R) was confirmed by dideoxy sequencing (Sanger et al., (1977) *Proc. Natl. Acad. Sci.*, (USA) 74:5460-5463) to be a *Lol p* V clone in the correct reading frame for expression.

5 The pET-11d *Lol p* V clone was grown on a large scale for recombinant protein expression and purification. A 2 ml culture of bacteria containing the recombinant plasmid was grown for 8 hr, then streaked onto solid media (e.g. 6 petri plates (100 x 15 mm) with 1.5% agarose in LB medium (Gibco-BRL, Gaithersburg, MD) containing 200 µg/ml ampicillin), grown to confluence overnight, then scraped into 9 L of liquid media (Brain Heart Infusion 10 media, Difco) containing ampicillin (200 µg/ml). The culture was grown until the A₆₀₀ was 1.0, IPTG added (1 mM final concentration), and the culture grown for an additional 2 hours.

Bacteria were recovered by centrifugation (7,930 x g, 10 min), and lysed in 90 ml of 6M Guanidine-HCl, 0.1M Na₂HPO₄, pH 8.0 for 1 hour with vigorous shaking. Insoluble material was removed by centrifugation (11,000 x g, 10 min, 4° C). The pH of the lysate was adjusted to 15 pH 8.0, and the lysate applied to an 80 ml Nickel NTA agarose column (Qiagen, Chatsworth, CA) that had been equilibrated with 6 M Guanidine HCl, 100 mM Na₂HPO₄, pH 8.0. The column was sequentially washed with 6 M Guanidine HCl, 100 mM Na₂HPO₄, 10 mM Tris-HCl, pH 8.0, then 8 M urea, 100 mM Na₂HPO₄, pH 8.0, and finally 8 M urea, 100 mM sodium acetate, 10 mM Tris-HCl, pH 6.3. The column was washed with each buffer until the flow 20 through had an A₂₈₀≤ 0.05.

The recombinant protein, r*Lol p* V, was eluted with 8 M urea, 100 mM sodium acetate, 10 mM Tris-HCl, pH 4.5, and collected in 10 ml aliquots. The protein concentration of each fraction was determined by absorbance at A₂₈₀ and the peak fractions pooled. An aliquot of the 25 collected recombinant protein was analyzed on SDS-PAGE (data not shown) according to the method in Sambrook et al., *supra*.

The first 9 liter preparation yielded 12 mg of r*Lol p* V with approximately 60-70% purity. Purity of the preparation was determined by densitometry (Shimadzu Flying Spot Scanner, Shimadzu Scientific Instruments, Inc., Braintree, MA) of the coomassie-blue stained SDS-PAGE 30 gel.

B160277 140625 200

Example 5- Cloning and Expression of *Dac g V*

Dactylis glomerata pollen was purchased from Greer Laboratories (Lenoir, NC). RNA was isolated as previously described in PCT/US92/05661 (WO93/01213) and polyA+ RNA was isolated using MICRO-FAST TRACK® mRNA isolation kit from Invitrogen (San Diego, CA). Double stranded cDNA was made with the BRL cDNA SYNTHESIS PLUS® kit (Gaithersburg, MD). A cDNA library was made in λgt10 using the cDNA CLONING SYSTEM: IGT10® (Amersham, Arlington Heights, IL). The *D. glomerata* double stranded cDNA was ligated with adaptor arms, containing *Eco RI*, *Bam HI*, *Kpn I* and *Nco I* restriction sites and ligated into (lambda) gt10 vector arms using the manufacturer's suggested protocols. The library was packaged and titred also using the manufacturer's suggested protocols. The library was plated out and over 100,000 independent phage plaques were screened using random primed (RANDOM PRIMED DNA LABELING KIT®, Boehringer Mannheim Corporation, Indianapolis, IN) or nick-translated probe [Sambrook J et al. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor: Cold Spring Harbor Laboratory, 1989]. The library was screened with the 1.2 kb *Lol p V* clone 12R cDNA [Singh MB et al, *Proc Natl Acad Sci USA*, 1991; 88: 1384-1388].

There were many positive clones identified in the first screen. Several clones were picked using standard techniques [Sambrook J et al. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor: Cold Spring Harbor Laboratory, 1989] and dilutions of high-titrated phage stocks were re-screened using the same *Lol p V* clone 12R probe. The phage stocks were prepared using standard techniques [Sambrook J et al. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor: Cold Spring Harbor Laboratory, 1989]. Positive clones were again picked, high-titrated stocks prepared as before and serial dilutions were prepared for tertiary screening with the *Lol p V* clone 12R probe. Six phage clones, 228, 235, 236, 259, 267, and 285, were positive after this tertiary screening and high titrated stocks were prepared as described [Sambrook J et al. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor: Cold Spring Harbor Laboratory, 1989]. The cDNA inserts were isolated from the selected phage using standard techniques [Sambrook J et al. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor: Cold Spring Harbor Laboratory, 1989]. The insert from clone 228 was approximately 500 base pairs (bp). The insert from clone 235 was approximately 1,000 bp. The insert from clone 236 was approximately 1200 bp. The insert from clone 259 was approximately 1,200 bp. The insert from clone 267 was approximately 1,000 bp. The insert from clone 285 was approximately 800 bp.

The isolated inserts were cloned into appropriately digested pUC18 and/or pUC19 for subsequent analysis. The cDNA inserts were sequenced using the SEQUENASE® kits (USB, Cleveland, OH) based on the standard dideoxy chain termination method of Sanger *et al.* [Sanger F et al. *Proc Natl Acad Sci USA*, 1977; 74: 5460-5463].

5 Partial sequences for all of the clones were determined. All were found to contain *Dac g V* sequences by comparison with *Lol p V* clone 12R sequence (SEQ ID NO:2) [Ong EK et al. *Gene*, 1993; 134: 235-240]. The partial translated sequences of clones 235 and 236 were very similar to each other, although they started at different sites in the sequence (not shown), and appear to represent one isoform of *Dac g V*. The partial translated sequence of clone 259 was
10 different from that of clones 235 and 236 and appear to represent a second isoform of *Dac g V*. The partial translated sequence of clone 259 is most homologous to the sequence of *Lol p V* clone 12R (SEQ ID NO:2) [Ong EK et al. *Gene* 1993; 134: 235-240]. The partial translated sequences of clones 235 and 236 are most closely homologous to the sequence of *Lol p V* clone 19R [Ong EK et al. *Gene* 1993; 134: 235-240].

15 Clone 259 was sequenced in its entirety. It was sequenced from both ends using standard forward and reverse primers (New England Biolabs, Beverly, MA). Subconstructs were prepared by digestion of isolated insert with *Eco RI* and *Pst I* and the fragments were cloned into appropriately digested pUC18 for internal sequencing. The *Eco RI/Pst I* insert that corresponded to the 5' portion of the *Dac g V* gene was isolated and further digested with *Stu I* or *Sau 3A* and
20 *Xho I* and ligated into appropriately digested pUC19 for further sequence analysis. The nucleotide (SEQ ID NO:57) and deduced amino acid (SEQ ID NO:58) sequence of clone 259 is shown in Figure 16. Nucleotides 1-25 correspond to adaptor sequence. The sequence ends with the poly A tract; the adaptor sequence is not shown at the 3' end of the sequence. The nucleotide sequence from 700 to 1181 is only preliminary and some bases may be misidentified. For
25 example, nucleotide 712 has been tentatively identified as a "C". However, this is the third position of the codon encoding Gly196 and the presence of another nucleotide at residue 712 would not change the predicted amino acid. It is difficult to sequence the Group V grass allergens due to their high GC content.

Clone 236 and 259 have been deposited with the ATCC.

30 As Group V allergens tend to have very conserved regions, the major T cell epitope containing peptides of *Lol p V* as described herein, are likely to be the major T cell epitopes of *Dac g V*, particularly where the regions are highly conserved between the related grasses.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

5

(i) APPLICANT: Griffith, Irwin J.
Kuo, Mei-Chang
Luqman, Mohammad

10

(ii) TITLE OF INVENTION: T CELL EPITOPES OF RYEGRASS POLLEN
ALLERGEN

(iii) NUMBER OF SEQUENCES: 58

15

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: LAHIVE & COCKFIELD
(B) STREET: 60 State Street, suite 510
(C) CITY: Boston
(D) STATE: Massachusetts
20 (E) COUNTRY: USA
(F) ZIP: 02109

20

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
25 (B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: ASCII Text

25

(vi) CURRENT APPLICATION DATA:

30

(A) APPLICATION NUMBER: US 08/106,016
(B) FILING DATE: 31-AUG-1993
(C) CLASSIFICATION:

35

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Amy E. Mandragouras
(B) REGISTRATION NUMBER: 36,207
(C) REFERENCE/DOCKET NUMBER: 075 (IMI-040cp2PC)

40

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (617) 227-7400
(B) TELEFAX: (617) 227-5941

45

(2) INFORMATION FOR SEQ ID NO:1:

45

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1229 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
50 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

DEPARTMENT OF COMMERCE
U.S. PATENT AND TRADEMARK OFFICE

(ix) FEATURE:
5 (A) NAME/KEY: CDS
 (B) LOCATION: 40..942

(ix) FEATURE:
10 (A) NAME/KEY: mat_peptide
 (B) LOCATION: 115..940

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

15	CGCTATCCCT CCCTCGTACA AACAAACGCA AGAGCAGCA ATG GCC GTC CAG AAG Met Ala Val Gln Lys -25	54
20	TAC ACG GTG GCT CTA TTC CTC GCC GTG GCC CTC GTG GCG GGC CCG GCC Tyr Thr Val Ala Leu Phe Leu Ala Val Ala Leu Val Ala Gly Pro Ala -20 -15 -10 -5	102
25	GCC TCC TAC GCC GCT GAC GCC GGC TAC ACC CCC GCA GCC GCG GCC ACC Ala Ser Tyr Ala Ala Asp Ala Gly Tyr Thr Pro Ala Ala Ala Ala Thr 1 5 10	150
30	CCG GCT ACT CCT GCT GCC ACC CCG GCT GCG GCT GGA GGG AAG GCG ACG Pro Ala Thr Pro Ala Ala Thr Pro Ala Ala Ala Gly Gly Lys Ala Thr 15 20 25	198
35	ACC GAC GAG CAG AAG CTG CTG GAG GAC GTC AAC GCT GGC TTC AAG GCA Thr Asp Glu Gln Lys Leu Leu Glu Asp Val Asn Ala Gly Phe Lys Ala 30 35 40	246
40	GCC GTG GCC GCC GCT GCC AAC GCC CCT CCG GCG GAC AAG TTC AAG ATC Ala Val Ala Ala Ala Asn Ala Pro Pro Ala Asp Lys Phe Lys Ile 45 50 55 60	294
45	TTC GAG GCC GCC TTC TCC GAG TCC TCC AAG GGC CTC CTC GCC ACC TCC Phe Glu Ala Ala Phe Ser Glu Ser Ser Lys Gly Leu Leu Ala Thr Ser 65 70 75	342
50	GCC GCC AAG GCA CCC GGC CTC ATC CCC AAG CTC GAC ACC GCC TAC GAC Ala Ala Lys Ala Pro Gly Leu Ile Pro Lys Leu Asp Thr Ala Tyr Asp 80 85 90	390
55	GTC GCC TAC AAG GCC GCC GAG GGC GCC ACC CCC GAG GCC AAG TAC GAC Val Ala Tyr Lys Ala Ala Glu Gly Ala Thr Pro Glu Ala Lys Tyr Asp 95 100 105	438

	GCC TTC GTC ACT GCC CTC ACC GAA GCG CTC CGC GTC ATC GCC GGC GCC	486	
	Ala Phe Val Thr Ala Leu Thr Glu Ala Leu Arg Val Ile Ala Gly Ala		
110	115	120	
5	CTC GAG GTC CAC GCC GTC AAG CCC GCC ACC GAG GAG GTC CCT GCT GCT	534	
	Leu Glu Val His Ala Val Lys Pro Ala Thr Glu Glu Val Pro Ala Ala		
125	130	135	
10	AAG ATC CCC ACC GGT GAG CTG CAG ATC GTT GAC AAG ATC GAT GCT GCC	582	
	Lys Ile Pro Thr Gly Glu Leu Gln Ile Val Asp Lys Ile Asp Ala Ala		
	145	150	155
15	TTC AAG ATC GCA GCC ACC GCC AAC GCC CCC ACC AAC GAT AAG	630	
	Phe Lys Ile Ala Ala Thr Ala Ala Asn Ala Ala Pro Thr Asn Asp Lys		
	160	165	170
20	TTC ACC GTC TTC GAG AGT GCC TTC AAC AAG GCC CTC AAT GAG TGC ACG	678	
	Phe Thr Val Phe Glu Ser Ala Phe Asn Lys Ala Leu Asn Glu Cys Thr		
	175	180	185
	GGC GGC GCC TAT GAG ACC TAC AAG TTC ATC CCC TCC CTC GAG GCC GCG	726	
	Gly Gly Ala Tyr Glu Thr Tyr Lys Phe Ile Pro Ser Leu Glu Ala Ala		
	190	195	200
25	GTC AAG CAG GCC TAC GCC ACC GTC GCC GCG CCC GAG GTC AAG	774	
	Val Lys Gln Ala Tyr Ala Ala Thr Val Ala Ala Pro Glu Val Lys		
	205	210	215
30	TAC GCC GTC TTT GAG GCC GCG CTG ACC AAG GCC ATC ACC GCC ATG ACC	822	
	Tyr Ala Val Phe Glu Ala Ala Leu Thr Lys Ala Ile Thr Ala Met Thr		
	225	230	235
35	CAG GCA CAG AAG GCC GGC AAA CCC GCT GCC GCG GCT GCC ACA GGC GCC	870	
	Gln Ala Gln Lys Ala Gly Lys Pro Ala Ala Ala Ala Thr Gly Ala		
	240	245	250
40	GCA ACC GTT GCC ACC GGC GCA ACC GCC GCG GGT GCT GCC ACC	918	
	Ala Thr Val Ala Thr Gly Ala Ala Thr Ala Ala Gly Ala Ala Thr		
	255	260	265
	GCC GCT GGT GGC TAC AAA GCC TGATCAGCTT GCTAATATAC TACTGAACGT	972	
	Ala Ala Ala Gly Gly Tyr Lys Ala		
	270	275	
45	ATGTATGTGC ATGATCCGGG CGGCGAGTGG TTTTGTTGAT AATTAATCTT CGTTTTCGTT	1032	
	TCATGCAGCC GCGATCGAGA GGGCTTGCAT GCTTGTAAATA ATTCAATATT TTTCATTCT	1092	
50	TTTTGAATCT GTAAATCCCC ATGACAAGTA GTGGGATCAA GTCGGCATGT ATCACCGTTG	1152	
	ATGCGAGTTT AACGATGGGG AGTTTATCAA AGAATTATT ATTAAAAAAA AAAAAAAA	1212	

AAAAAAAAAA AAAAAAA

1229

5 (2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 301 amino acids
(B) TYPE: amino acid
10 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

15 Met Ala Val Gln Lys Tyr Thr Val Ala Leu Phe Leu Ala Val Ala Leu
-25 -20 -15 -10

20 Val Ala Gly Pro Ala Ala Ser Tyr Ala Ala Asp Ala Gly Tyr Thr Pro
-5 1 5

Ala Ala Ala Ala Thr Pro Ala Thr Pro Ala Ala Thr Pro Ala Ala Ala
10 15 20

25 Gly Gly Lys Ala Thr Thr Asp Glu Gln Lys Leu Leu Glu Asp Val Asn
25 30 35

30 Ala Gly Phe Lys Ala Ala Val Ala Ala Ala Asn Ala Pro Pro Ala
40 45 50 55

35 Asp Lys Phe Lys Ile Phe Glu Ala Ala Phe Ser Glu Ser Ser Lys Gly
60 65 70

Leu Leu Ala Thr Ser Ala Ala Lys Ala Pro Gly Leu Ile Pro Lys Leu
35 75 80 85

40 Asp Thr Ala Tyr Asp Val Ala Tyr Lys Ala Ala Glu Gly Ala Thr Pro
90 95 100

45 Glu Ala Lys Tyr Asp Ala Phe Val Thr Ala Leu Thr Glu Ala Leu Arg
105 110 115

Val Ile Ala Gly Ala Leu Glu Val His Ala Val Lys Pro Ala Thr Glu
120 125 130 135

45 Glu Val Pro Ala Ala Lys Ile Pro Thr Gly Glu Leu Gln Ile Val Asp
140 145 150

50 Lys Ile Asp Ala Ala Phe Lys Ile Ala Ala Thr Ala Ala Asn Ala Ala
155 160 165

Pro Thr Asn Asp Lys Phe Thr Val Phe Glu Ser Ala Phe Asn Lys Ala

5

00

-51-

170

175

180

Leu Asn Glu Cys Thr Gly Gly Ala Tyr Glu Thr Tyr Lys Phe Ile Pro
185 190 195

5 Ser Leu Glu Ala Ala Val Lys Gln Ala Tyr Ala Ala Thr Val Ala Ala
200 205 210 215

Ala Pro Glu Val Lys Tyr Ala Val Phe Glu Ala Ala Leu Thr Lys Ala
10 220 225 230

Ile Thr Ala Met Thr Gln Ala Gln Lys Ala Gly Lys Pro Ala Ala Ala
235 240 245

Ala Ala Thr Gly Ala Ala Thr Val Ala Thr Gly Ala Ala Thr Ala Ala
15 250 255 260

Ala Gly Ala Ala Thr Ala Ala Gly Gly Tyr Lys Ala
265 270 275

20 (2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

25 (ii) MOLECULE TYPE: peptide

30 (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

35 Ala Asp Ala Gly Tyr Thr Pro Ala Ala Ala Ala Thr Pro Ala Thr Pro
1 5 10 15

40 Ala Ala Thr Pro
20

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

45 (ii) MOLECULE TYPE: peptide

50 (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

5 Ala Thr Pro Ala Thr Pro Ala Ala Thr Pro Ala Ala Ala Gly Gly Lys
1 5 10 15

Ala Thr Thr Asp
20

10 (2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
15 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide
20 (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

25 Ala Ala Ala Gly Gly Lys Ala Thr Thr Asp Glu Gln Lys Leu Leu Glu
1 5 10 15

Asp Val Asn Ala
30 20

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
35 (B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide
40 (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

45 Glu Gln Lys Leu Leu Glu Asp Val Asn Ala Gly Phe Lys Ala Ala Val
1 5 10 15

Ala Ala Ala Ala
50 20

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:
5 (A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

10 (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

15 Gly Phe Lys Ala Ala Val Ala Ala Ala Ala Asn Ala Pro Pro Ala Asp
1 5 10 15

20 Lys Phe Lys Ile
20

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:
25 (A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

30 (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

35 Asn Ala Pro Pro Ala Asp Lys Phe Lys Ile Phe Glu Ala Ala Phe Ser
1 5 10 15

40 Glu Ser Ser Lys
20

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:
45 (A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

50 (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

5 Phe Glu Ala Ala Phe Ser Glu Ser Ser Lys Gly Leu Leu Ala Thr Ser
1 5 10 15
Ala Ala Lys Ala
20

10 (2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:
15 (A) LENGTH: 20 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
20 (ii) MOLECULE TYPE: peptide
 (v) FRAGMENT TYPE: internal

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

25 Gly Leu Leu Ala Thr Ser Ala Ala Lys Ala Pro Gly Leu Ile Pro Lys
1 5 10 15
Leu Asp Thr Ala
30 20

30 (2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:
35 (A) LENGTH: 20 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
40 (ii) MOLECULE TYPE: peptide
 (v) FRAGMENT TYPE: internal

45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

45 Pro Gly Leu Ile Pro Lys Leu Asp Thr Ala Tyr Asp Val Ala Tyr Lys
1 5 10 15
50 Ala Ala Glu Gly
20

(2) INFORMATION FOR SEQ ID NO:12:

5 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: peptide

15 (v) FRAGMENT TYPE: internal

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Tyr Asp Val Ala Tyr Lys Ala Ala Glu Gly Ala Thr Pro Glu Ala Lys
1 5 10 15

20 Tyr Asp Ala Phe
20

(2) INFORMATION FOR SEQ ID NO:13:

25 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Ala Thr Pro Glu Ala Lys Tyr Asp Ala Phe Val Thr Ala Leu Thr Glu
1 5 10 15

40 Ala Leu Arg Val
20

(2) INFORMATION FOR SEQ ID NO:14:

45 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

50 (ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Val Thr Ala Leu Thr Glu Ala Leu Arg Val Ile Ala Gly Ala Leu Glu
1 5 10 15

10 Val His Ala Val
20

(2) INFORMATION FOR SEQ ID NO:15:

15 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

20 (ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Ile Ala Gly Ala Leu Glu Val His Ala Val Lys Pro Ala Thr Glu Glu
1 5 10 15

30 Val Pro Ala Ala
20

(2) INFORMATION FOR SEQ ID NO:16:

35 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

40 (ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

50 Lys Pro Ala Thr Glu Glu Val Pro Ala Ala Lys Ile Pro Thr Gly Glu
1 5 10 15

Leu Gln Ile Val

20

(2) INFORMATION FOR SEQ ID NO:17:

5 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

Lys Ile Pro Thr Gly Glu Leu Gln Ile Val Asp Lys Ile Asp Ala Ala
1 5 10 15
Phe Lys Ile Ala
20

25 (2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

Asp Lys Ile Asp Ala Ala Phe Lys Ile Ala Ala Thr Ala Ala Asn Ala
40 1 5 10 15
Ala Pro Thr Asn
20

45 (2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

50 (ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

Ala Thr Ala Ala Asn Ala Ala Pro Thr Asn Asp Lys Phe Thr Val Phe
1 5 10 15

10

Glu Ser Ala Phe
20

15

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

20

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

Asp Lys Phe Thr Val Phe Glu Ser Ala Phe Asn Lys Ala Leu Asn Glu
1 5 10 15

30

Cys Thr Gly Gly
20

35 (2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

40

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

50

Asn Lys Ala Leu Asn Glu Cys Thr Gly Gly Ala Tyr Glu Thr Tyr Lys
1 5 10 15

Phe Ile Pro Ser
20

5

(2) INFORMATION FOR SEQ ID NO:22:

10 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: peptide
(v) FRAGMENT TYPE: internal

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

Ala Tyr Glu Thr Tyr Lys Phe Ile Pro Ser Leu Glu Ala Ala Val Lys
1 5 10 15

Gln Ala Tyr Ala
20

30 (2) INFORMATION FOR SEQ ID NO:23:

35 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide
(v) FRAGMENT TYPE: internal

40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

45 Leu Glu Ala Ala Val Lys Gln Ala Tyr Ala Ala Thr Val Ala Ala Ala
1 5 10 15

Pro Glu Val Lys
20

50 (2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

5 (ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

Ala Thr Val Ala Ala Ala Pro Glu Val Lys Tyr Ala Val Phe Glu Ala
1 5 10 15

15 Ala Leu Thr Lys
20

20 (2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

25 (ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

Tyr Ala Val Phe Glu Ala Ala Leu Thr Lys Ala Ile Thr Ala Met Thr
1 5 10 15

35 Gln Ala Gln Lys
20

40 (2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

45 (ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

Ala Ile Thr Ala Met Thr Gln Ala Gln Lys Ala Gly Lys Pro Ala Ala
1 5 10 15
Ala Ala Ala Thr
20

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

Ala Gly Lys Pro Ala Ala Ala Ala Thr Gly Ala Ala Thr Val Ala
1 5 10 15
Thr Gly Ala Ala
20

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

Gly Ala Ala Thr Val Ala Thr Gly Ala Ala Ala Ala Gly Ala
1 5 10 15
Ala Thr Ala Ala
20

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:
5 (A) LENGTH: 16 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

10 (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

15 Thr Ala Ala Ala Gly Ala Ala Thr Ala Ala Ala Gly Gly Tyr Lys Ala.
1 5 10 15

20 (2) INFORMATION FOR SEQ ID NO:30:

25 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: peptide

35 (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

35 Ile Ala Lys Val Pro Pro Gly Pro Asn Ile Thr Ala Glu Tyr Gly Asp
1 5 10 15

Lys Trp Leu Asp
20

40 (2) INFORMATION FOR SEQ ID NO:31:

45 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

50 (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

5 Ile Ala Lys Val Xaa Pro Gly Xaa Asn Ile Thr Ala Glu Tyr Gly Asp
1 5 10 15

Lys Trp Leu Asp
20

10 (2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:
15 (A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

20 (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

25 Thr Ala Glu Tyr Gly Asp Lys Trp Leu Asp Ala Lys Ser Thr Trp Tyr
1 5 10 15

Gly Lys Pro Thr
20

30 (2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:
35 (A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

40 (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

45 Gly Ala Gly Pro Lys Asp Asn Gly Gly Ala Cys Gly Tyr Lys Asn Val
1 5 10 15

Asp Lys Ala Pro
50 20

(2) INFORMATION FOR SEQ ID NO:34:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 20 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

Gly Ala Gly Pro Lys Asp Asn Gly Gly Ala Cys Gly Tyr Lys Asp Val
1 5 10 15

Asp Lys Ala Pro
20

(2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 20 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

Cys Gly Tyr Lys Asp Val Asp Lys Ala Pro Phe Asn Gly Met Thr Gly
1 5 10 15

Cys Gly Asn Thr
20

(2) INFORMATION FOR SEQ ID NO:36:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 20 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

THE UNIVERSITY OF TORONTO LIBRARIES

C

C

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

5 Phe Asn Gly Met Thr Gly Cys Gly Asn Thr Pro Ile Phe Lys Asp Gly
1 5 10 15
Arg Gly Cys Gly
20

10 (2) INFORMATION FOR SEQ ID NO:37:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
15 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

25 Pro Ile Phe Lys Asp Gly Arg Gly Cys Gly Ser Cys Phe Glu Ile Lys
1 5 10 15
Cys Thr Lys Pro
30 20

30 (2) INFORMATION FOR SEQ ID NO:38:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
35 (B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

45 Ser Cys Phe Glu Ile Lys Cys Thr Lys Pro Glu Ser Cys Ser Gly Glu
1 5 10 15
Ala Val Thr Val
50 20

(2) INFORMATION FOR SEQ ID NO:39:

(i) SEQUENCE CHARACTERISTICS:
5 (A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

10 (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

15 Glu Ser Cys Ser Gly Glu Ala Val Thr Val Thr Ile Thr Asp Asp Asn
1 5 10 15

20 Glu Glu Pro Ile
20

(2) INFORMATION FOR SEQ ID NO:40:

(i) SEQUENCE CHARACTERISTICS:
25 (A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

30 (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

35 Thr Ile Thr Asp Asp Asn Glu Glu Pro Ile Ala Pro Tyr His Phe Asp
1 5 10 15

40 Leu Ser Gly His
20

(2) INFORMATION FOR SEQ ID NO:41:

(i) SEQUENCE CHARACTERISTICS:
45 (A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

50 (v) FRAGMENT TYPE: internal

4

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

5 Ala Pro Tyr His Phe Asp Leu Ser Gly His Ala Phe Gly Ser Met Ala
1 5 10 15

Asp Asp Gly Glu
20

10 (2) INFORMATION FOR SEQ ID NO:42:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
15 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

20 (v) FRAGMENT TYPE: internal

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

Ala Phe Gly Ser Met Ala Asp Asp Gly Glu Glu Gln Lys Leu Arg Ser
1 5 10 15

30 Ala Gly Glu Leu
20

(2) INFORMATION FOR SEQ ID NO:43:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
35 (B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

40 (v) FRAGMENT TYPE: internal

45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

Glu Gln Lys Leu Arg Ser Ala Gly Glu Leu Glu Leu Gln Phe Arg Arg
1 5 10 15

50 Val Lys Cys Lys
20

(2) INFORMATION FOR SEQ ID NO:44:

5 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
- (B) TYPE: amino acid
- (C) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: peptide

15 (v) FRAGMENT TYPE: internal

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

Glu Leu Gln Phe Arg Arg Val Lys Cys Lys Tyr Pro Asp Asp Thr Lys
1 5 10 15

20 Pro Thr Phe His
20

(2) INFORMATION FOR SEQ ID NO:45:

25 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
- (B) TYPE: amino acid
- (C) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

Tyr Pro Asp Asp Thr Lys Pro Thr Phe His Val Glu Lys Ala Ser Asn
1 5 10 15

40 Pro Asn Tyr Leu
20

(2) INFORMATION FOR SEQ ID NO:46:

45 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
- (B) TYPE: amino acid
- (C) TOPOLOGY: linear

50 (ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

Val Glu Lys Ala Ser Asn Pro Asn Tyr Leu Ala Ile Leu Val Lys Tyr
1 5 10 15

10 Val Asp Gly Asp
20

(2) INFORMATION FOR SEQ ID NO:47:

15 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

20 (ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

Val Glu Lys Gly Ser Asn Pro Asn Tyr Leu Ala Ile Leu Val Lys Tyr
1 5 10 15

30 Val Asp Gly Asp
20

(2) INFORMATION FOR SEQ ID NO:48:

35 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

40 (ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

Ala Ile Leu Val Lys Tyr Val Asp Gly Asp Val Val Ala Val
1 5 10 15

50 Asp Ile Lys Glu

20

(2) INFORMATION FOR SEQ ID NO:49:

5 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
- (B) TYPE: amino acid
- (C) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: peptide

15 (v) FRAGMENT TYPE: internal

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:

Gly Asp Val Val Ala Val Asp Ile Lys Glu Lys Gly Lys Asp Lys Trp
1 5 10 15

20 Ile Glu Leu Lys
20

(2) INFORMATION FOR SEQ ID NO:50:

25 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
- (B) TYPE: amino acid
- (C) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:

Lys Gly Lys Asp Lys Trp Ile Glu Leu Lys Glu Ser Trp Gly Ala Val
1 5 10 15

40 Trp Arg Ile Asp
20

(2) INFORMATION FOR SEQ ID NO:51:

45 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
- (B) TYPE: amino acid
- (C) TOPOLOGY: linear

50 (ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:

Thr Pro Asp Lys Leu Thr Gly Pro Phe Thr Val Arg Tyr Thr Thr Glu
1 5 10 15

10 Gly Gly Thr Lys
20

(2) INFORMATION FOR SEQ ID NO:52:

15 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

20 (ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:

Val Arg Tyr Thr Thr Glu Gly Gly Thr Lys Ser Glu Val Glu Asp Val
1 5 10 15

30 Ile Pro Glu Gly
20

35 (2) INFORMATION FOR SEQ ID NO:53:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

40 (ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:

50 Ser Glu Val Glu Asp Val Ile Pro Glu Gly Trp Lys Ala Asp Thr Ser
1 5 10 15

Tyr Ser Ala Lys

(2) INFORMATION FOR SEQ ID NO:54:

5 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 33 amino acids
- (B) TYPE: amino acid
- (C) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: peptide

10 (v) FRAGMENT TYPE: N-terminal

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:

Ala Asp Ala Gly Tyr Thr Hyp Ala Ala Ala Ala Thr Hyp Ala Thr Hyp
1 5 10 15

20 Ala Ala Thr Hyp Ala Ala Ala Gly Gly Lys Ala Thr Thr Asp Glu Gln
20 25 30

Lys

25 (2) INFORMATION FOR SEQ ID NO:55:

30 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
- (B) TYPE: amino acid
- (C) TOPOLOGY: linear

35 (ii) MOLECULE TYPE: peptide

35 (v) FRAGMENT TYPE: internal

40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:

Ala Lys Ser Thr Trp Tyr Gly Lys Pro Thr Gly Ala Gly Pro Lys Asp
1 5 10 15

45 Asn Gly Gly Ala
20

(2) INFORMATION FOR SEQ ID NO:56:

50 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
- (B) TYPE: amino acid
- (C) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:

Glu Ser Trp Gly Ala Val Trp Arg Ile Asp Thr Pro Asp Lys Leu Thr
1 5 10 15
Gly Pro Phe Thr
20

(2) INFORMATION FOR SEQ ID NO:57:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1181 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: CDS
(B) LOCATION: 53..124

(ix) FEATURE:

(A) NAME/KEY: CDS
(B) LOCATION: 125..961

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:

GAATTCTGAGG ATCCGGGTAC CATGGCTCCG ACAAACCAAC GCAAGAGCAG CA ATG 55
Met

GCA GTG CAG CAG TAC ACG GTG GCG CTG TTC CTG GCC GTG GCC TCG TGT 103
Ala Val Gln Gln Tyr Thr Val Ala Leu Phe Leu Ala Val Ala Ser Cys
-20 -15 -10

CGG GCC CGC GCC TCC TAC GCC GAC GGC TAC GCC CCC GCC ACT 151
Arg Ala Arg Ala Ser Tyr Ala Ala Asp Ala Gly Tyr Ala Pro Ala Thr
-5 1 5

CCC GCC ACC CCG GCT ACC CCC GCG GCC CCA GGC GCA GCG GTG CCA GCA 199
Pro Ala Thr Pro Ala Thr Pro Ala Ala Pro Gly Ala Ala Val Pro Ala
10 15 20 25

	GGG AAG GCG GCG ACC GAG GAG CAG AAG CTG ATC GAG AAG ATC AAC GCC Gly Lys Ala Ala Thr Glu Glu Gln Lys Leu Ile Glu Lys Ile Asn Ala	247
5	30 35 40	
	GGC TTC AAG GCC GCC GTG GCG GCC GCG GGC GTC CCG CCA GGC GAC Gly Phe Lys Ala Ala Val Ala Ala Gly Val Pro Pro Gly Asp	295
	45 50 55	
10	AAG TAC AAG ACG TTC GTC GAA ACC TTC GGC AAG GCC TCC AAC AAG GCC Lys Tyr Lys Thr Phe Val Glu Thr Phe Gly Lys Ala Ser Asn Lys Ala	343
	60 65 70	
15	TTC CTG GGG GAC CTC CCG ACC AAC TAC GCC GAT GTC AAC TCC AGG GCC Phe Leu Gly Asp Leu Pro Thr Asn Tyr Ala Asp Val Asn Ser Arg Ala	391
	75 80 85	
20	CAG CTC ACC TCG AAG CTC GAC GCC GCC TAC AAG CTC GCC TAC GAC GCC Gln Leu Thr Ser Lys Leu Asp Ala Ala Tyr Lys Leu Ala Tyr Asp Ala	439
	90 95 100 105	
	GCC CAG GGC GCC ACC CCC GAG GCC AAG TAC GAC GCC TAC GTC GCC ACC Ala Gln Gly Ala Thr Pro Glu Ala Lys Tyr Asp Ala Tyr Val Ala Thr	487
25	110 115 120	
	CTC AGC GAG GCG CTC CGC ATC ATC GCC GGC ACC CTC GAG GTC CAC GCC Leu Ser Glu Ala Leu Arg Ile Ile Ala Gly Thr Leu Glu Val His Ala	535
	125 130 135	
30	GTC AAG CCC GCT GCC GAG GAG GTC AAG CCT ATC CCC GCC GGA GAG CTG Val Lys Pro Ala Ala Glu Glu Val Lys Pro Ile Pro Ala Gly Glu Leu	583
	140 145 150	
35	CAG ATC GTC GAC AAG ATT GAC GTC GCC TTC AGA ACT GCC GCC ACC GCC Gln Ile Val Asp Lys Ile Asp Val Ala Phe Arg Thr Ala Ala Thr Ala	631
	155 160 165	
40	GCC AAC GCC GCC CCC ACC AAC GAC AAG TTC ACC GTA TTC GAG ACC ACC Ala Asn Ala Ala Pro Thr Asn Asp Lys Phe Thr Val Phe Glu Thr Thr	679
	170 175 180 185	
	TTT AAC AAG GCC ATC AAG GAG AGC ACG GGC GGC ACC ACC TAC GAG AGC TAC Phe Asn Lys Ala Ile Lys Glu Ser Thr Gly Gly Thr Tyr Glu Ser Tyr	727
45	190 195 200	
	AAG TTC ATT CCC ACC CTT GAG GCC GCC GTT AAG CAG GGC TAC GCC GCC Lys Phe Ile Pro Thr Leu Glu Ala Ala Val Lys Gln Ala Tyr Ala Ala	775
	205 210 215	
50	ACC GTC GCA TCC GCG CCG GAG GTC AAG TAC GCC GTC TTT GAG ACC GCG Thr Val Ala Ser Ala Pro Glu Val Lys Tyr Ala Val Phe Glu Thr Ala	823
	220 225 230	

CTG AAA AAG GCG GTC ACC GCC ATG TCC GAG GCC CAG AAG GAA GCC AAG
 Leu Lys Lys Ala Val Thr Ala Met Ser Glu Ala Gln Lys Glu Ala Lys
 235 240 245

5 CCC GCC ACC GCC ACC CCG ACC CCC ACC GCA ACT GCC GCG GCC GCG GTG
 Pro Ala Thr Ala Thr Pro Thr Pro Thr Ala Thr Ala Ala Ala Ala Val
 250 255 260 265

10 GCC ACC AAC GCC GCC CCC GTC GCT GGT GGC TAC AAA ATC
 Ala Thr Asn Ala Ala Pro Val Ala Ala Gly Gly Tyr Lys Ile
 270 275

15 TGATCAAACTC GCTAGCAATA TACACATCCA TCATGCACAT ATAGAGCTGT GTATGTATGT
 GCATGCATGC CGTGGCGCCG CGCAAGTTTG CTCATAATTAA ATTCTTGGTT TTCGTTGCTT
 GCATCCACGA GCGACCGAGC CCGTGGATAG TCCGATGTGT ATGTAATTAA TTCTGAGAAA

20 TGTGTATATG TAATATATAA TTGAGTACTA AAAAAAAA

(2) INFORMATION FOR SEQ ID NO 58:

25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 279 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

35 Ala Asp Ala Gly Tyr Ala Pro Ala Thr Pro Ala Thr Pro Ala Thr Pro
 1 5 10 15

Ala Ala Pro Gly Ala Ala Val Pro Ala Gly Lys Ala Ala Thr Glu Glu
 20 25 30

40 Gln Lys Leu Ile Glu Lys Ile Asn Ala Gly Phe Lys Ala Ala Val Ala
 35 40 45

45 Ala Ala Ala Gly Val Pro Pro Gly Asp Lys Tyr Lys Thr Phe Val Glu
 50 55 60

Thr Phe Gly Lys Ala Ser Asn Lys Ala Phe Leu Gly Asp Leu Pro Thr
 65 70 75 80

50 Asn Tyr Ala Asp Val Asn Ser Arg Ala Gln Leu Thr Ser Lys Leu Asp
 85 90 95

Ala Ala Tyr Lys Leu Ala Tyr Asp Ala Ala Gln Gly Ala Thr Pro Glu

Claims

What is claimed is:

5 1. An isolated peptide of *Lol p V* wherein said peptide comprises at least one T cell epitope of *Lol p V*, said peptide having at least 7, but no more than 100, amino acid residues comprising an amino acid sequence selected from the group consisting of amino acid sequences as shown in Fig. 2 of peptides LPIX-1 (SEQ ID NO:3), LPIX-1.1 (SEQ ID NO:3), LPIX-2 (SEQ ID NO:4), LPIX-2.1 (SEQ ID NO: 4), LPIX-3 (SEQ ID NO:5), LPIX-4 (SEQ
10 ID NO:6) LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-7 (SEQ ID NO:9), LPIX-8 (SEQ ID NO:10), LPIX-9 (SEQ ID NO:11), LPIX-10 (SEQ ID NO:12), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-13 (SEQ ID NO:15), LPIX-14 (SEQ ID NO:16), LPIX-15 (SEQ ID NO:17), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-18 (SEQ ID NO:20), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-21 (SEQ ID NO:23), LPIX-22 (SEQ ID NO:24), LPIX-23 (SEQ ID NO:25), LPIX-24 (SEQ ID NO:26), LPIX-26 (SEQ ID NO:28), and LPIX-27 (SEQ ID NO:29).

2. An isolated peptide of claim 1, said peptide having at least 7, but no more than 10, amino acid residues comprising an amino acid sequence selected from the group consisting of the amino acid sequences as shown in Fig. 2 of peptides LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-8 (SEQ ID NO:10), LPIX-9 (SEQ ID NO:11), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-20 (SEQ ID NO:22), LPIX-23 (SEQ ID NO:25), and LPIX-26 (SEQ ID NO:28).

25 3. A peptide comprising a portion of an isolated peptide of claim 1 which has a T cell stimulation index of at least 2.0.

4. A peptide comprising a portion of an isolated peptide of claim 1 which has a T cell stimulation index approximately equivalent to or greater than the T cell stimulation index of said isolated peptide from which it is derived.

30 5. An isolated peptide of claim 1 which, when administered to an individual sensitive to *Lol p V* allergen, induces T cells to become nonresponsive or modifies the lymphokine secretion profile of T cells in the individual.

35

AMENDED SHEET
IPEA/EP

100 105 110

Ala Lys Tyr Asp Ala Tyr Val Ala Thr Leu Ser Glu Ala Leu Arg Ile
115 120 125

5 Ile Ala Gly Thr Leu Glu Val His Ala Val Lys Pro Ala Ala Glu Glu
130 135 140

10 Val Lys Pro Ile Pro Ala Gly Glu Leu Gln Ile Val Asp Lys Ile Asp
145 150 155 160

Val Ala Phe Arg Thr Ala Ala Thr Ala Ala Asn Ala Ala Pro Thr Asn
165 170 175

15 Asp Lys Phe Thr Val Phe Glu Thr Thr Phe Asn Lys Ala Ile Lys Glu
180 185 190

Ser Thr Gly Gly Thr Tyr Glu Ser Tyr Lys Phe Ile Pro Thr Leu Glu
195 200 205

20 Ala Ala Val Lys Gln Ala Tyr Ala Ala Thr Val Ala Ser Ala Pro Glu
210 215 220

25 Val Lys Tyr Ala Val Phe Glu Thr Ala Leu Lys Lys Ala Val Thr Ala
225 230 235 240

Met Ser Glu Ala Gln Lys Glu Ala Lys Pro Ala Thr Ala Thr Pro Thr
245 250 255

30 Pro Thr Ala Thr Ala Ala Ala Val Ala Thr Asn Ala Ala Pro Val
260 265 270

Ala Ala Gly Gly Tyr Lys Ile
275

35

6. An isolated peptide of claim 2 which binds immunoglobulin E to a substantially lesser extent than native *Lol p V* binds immunoglobulin E.

7. An isolated nucleic acid sequence having a sequence encoding a peptide of claim 1.

5 8. A functional equivalent of a nucleic acid sequence encoding a peptide of claim 1.

9. An isolated peptide which is immunologically cross-reactive with T cells reactive with a peptide of claim 2.

10 10. An isolated peptide of *Lol p V* wherein said peptide has a T cell stimulation index of at least about 3.5.

15 11. An isolated peptide of claim 10 wherein said T cell stimulation index is at least about 5.

12. A peptide of claim 1 modified to improve solubility.

13. A peptide of claim 2 modified to improve solubility.

20 14. A modified peptide of claim 13 which does not bind immunoglobulin E specific for *Lol p V* in a substantial percentage of individuals sensitive to *Lol p V*, or if binding of the peptide to said immunoglobulin E occurs, such binding does not result in release of mediators from mast cells or basophils in a substantial percentage of individuals sensitive to *Lol p V*.

25 15. A modified peptide of claim 12 which modifies, in an individual sensitive to *Lol p V* to whom it is administered, the allergic response of the individual to a *Lol p V* allergen.

30 16. A monoclonal antibody specifically reactive with a peptide of claim 1.

17. An isolated peptide produced in a host cell transformed with the nucleic acid of claim 7.

18. An isolated peptide produced in a host cell transformed with the nucleic acid of claim 8.

19. An expression vector comprising a nucleic acid sequence coding for a peptide of claim 1.

20. An expression vector comprising the functional equivalent of a nucleic acid sequence coding for a peptide of claim 1.

10 21. A composition comprising at least one isolated peptide of claim 1 and a pharmaceutically acceptable carrier or diluent.

22. A composition of claim 21 comprising a combination of peptides selected from the group of combinations consisting of:

15 LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);
LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);
LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);
LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), and LPIX-20 (SEQ ID NO:22);
LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-11 (SEQ ID NO: 13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), and
20 LPIX-20 (SEQ ID NO:22);
LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-8 (SEQ ID NO: 10), LPIX-9 (SEQ ID NO: 11), LPIX-11 (SEQ ID NO: 13), LPIX-12 (SEQ ID NO:14),
LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO: 21), LPIX-20 (SEQ ID NO:22), LPIX-23 (SEQ ID NO:25), and LPIX-26 (SEQ ID NO:28);
30 LPIX-4 (SEQ ID NO:6), LPIX-11 (SEQ ID NO: 13), LPIX-16 (SEQ ID NO:18), and LPIX-20 (SEQ ID NO:22);
LPIX-4 (SEQ ID NO:6), LPIX-11 (SEQ ID NO: 13), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);

SEARCHED * 400625 E230

LPIX-4 (SEQ ID NO:6), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);

LPIX-5 (SEQ ID NO:7), LPIX-11 (SEQ ID NO: 13), LPIX-16 (SEQ ID NO:18), and LPIX-20 (SEQ ID NO:22);

5 LPIX-5 (SEQ ID NO:7), LPIX-11 (SEQ ID NO: 13), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);

LPIX-5 (SEQ ID NO:7), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);

10 LPIX-11 (SEQ ID NO: 13), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);

LPIX-4 (SEQ ID NO:6), LPIX-11 (SEQ ID NO: 13), and LPIX-20 (SEQ ID NO:22);

LPIX-4 (SEQ ID NO:6), LPIX-16 (SEQ ID NO:18), and LPIX-20 (SEQ ID NO:22);

LPIX-4 (SEQ ID NO:6), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);

15 LPIX-5 (SEQ ID NO:7), LPIX-11 (SEQ ID NO: 13), and LPIX-20 (SEQ ID NO:22);

LPIX-11 (SEQ ID NO: 13), LPIX-16 (SEQ ID NO:18), and LPIX-20 (SEQ ID NO:22);

LPIX-11 (SEQ ID NO: 13), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);

LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);

20 23. A composition comprising at least one isolated peptide of claim 13 and a pharmaceutically acceptable carrier or diluent.

24. A method of detecting sensitivity to *Lol p V* in an individual, *in vitro*, comprising combining a blood sample obtained from the individual with at least one peptide of claim 1, 25 under conditions appropriate for binding of blood components with the peptide, and determining the extent to which such binding occurs as indicative of sensitivity in the individual to ryegrass pollen.

25. A method of claim 24 wherein the extent to which binding occurs is determined by 30 assessing B cell function, T cell function, T cell proliferation or a combination of T cell proliferation and B cell function.

26. A composition comprising a pharmaceutically acceptable carrier or diluent and at least two peptides of claim 1 wherein said composition comprises a sufficient percentage of

the T cell epitopes of the *Lol p V* protein allergen such that upon administration of the composition to an individual sensitive to *Lol p V*, T cells of the individual become nonresponsive to said *Lol p V* protein allergen.

5 27. A peptide of claim 4 modified to improve solubility.

28. A composition comprising at least one isolated peptide of claim 27.

29. A composition comprising a pharmaceutically acceptable carrier or diluent and at
10 least two peptides, each peptide comprising at least one T cell epitope, wherein at least one peptide comprises an amino acid sequence or portion thereof derived from *Lol p V* which is selected from the group consisting of: LPIX-1 (SEQ ID NO:3), LPIX-1.1 (SEQ ID NO:3), LPIX-2 (SEQ ID NO:4), LPIX-2.1 (SEQ ID NO: 4), LPIX-3 (SEQ ID NO:5), LPIX-4 (SEQ ID NO:6) LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-7 (SEQ ID NO:9), LPIX-
15 8 (SEQ ID NO:10), LPIX-9 (SEQ ID NO:11), LPIX-10 (SEQ ID NO:12), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-13 (SEQ ID NO:15), LPIX-14 (SEQ ID NO:16), LPIX-15 (SEQ ID NO:17), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-18 (SEQ ID NO:20), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-21 (SEQ ID NO:23), LPIX-22 (SEQ ID NO:24), LPIX-23 (SEQ ID NO:25), LPIX-24 (SEQ ID NO:26), LPIX-26 (SEQ ID NO:28), and LPIX-27 (SEQ ID NO:29) (as shown in Fig. 2), and wherein at least one peptide comprises an amino acid sequence or portion thereof derived from *Lol p I* which is selected from the group consisting of: LPI-1 (SEQ ID NO:30), LPI-1.1 (SEQ ID NO:31), LPI-2 (SEQ ID NO:32), LPI-3 (SEQ ID NO:55), LPI-4 (SEQ ID NO:33), LPI-4.1 (SEQ. ID NO:34), LPI-5 (SEQ ID NO:35), LPI-6 (SEQ ID NO:36), LPI-7 (SEQ ID NO:37), LPI-8 (SEQ ID NO:38), LPI-9 (SEQ ID NO:39), LPI-10 (SEQ ID NO:40), LPI-11 (SEQ ID NO:41), LPI-12 (SEQ ID NO:42), LPI-13 (SEQ ID NO:43), LPI-14 (SEQ ID NO:44), LPI-15 (SEQ ID NO:45), LPI-16 (SEQ ID NO:46), LPI-16.1(SEQ ID NO:47), LPI-17 (SEQ ID NO:48), LPI-18 (SEQ ID NO:49), LPI-19 (SEQ ID NO:50), LPI-20 (SEQ ID NO:56), LPI-21 (SEQ ID NO:51), LPI-22 (SEQ ID NO:52), and LPI-23 (SEQ ID NO:53) (as shown in Fig. 3).

30. A composition of claim 29 comprising a combination of peptides selected from the group of combinations consisting of:

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-8 (SEQ ID NO:10), LPIX-9 (SEQ ID NO:11),
5 LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-23 (SEQ ID NO:25), LPIX-26 (SEQ ID NO:28);

10 LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-9 (SEQ ID NO:11), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-9 (SEQ ID NO:11), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-23 (SEQ ID NO:25);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18),
LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19),
LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19),
LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-22 (SEQ ID NO:52), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-8 (SEQ ID NO:10),
LPIX-9 (SEQ ID NO:11), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22),
LPIX-23 (SEQ ID NO:25), LPIX-26 (SEQ ID NO:28);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-22 (SEQ ID NO:52), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-9 (SEQ ID NO:11),
LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

2025ETEST

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-22 (SEQ ID NO:52), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-9 (SEQ ID NO:11),
5 LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-23 (SEQ ID NO:25);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-22 (SEQ ID NO:52), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-12 (SEQ ID NO:14),
10 LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-22 (SEQ ID NO:52), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-16 (SEQ ID NO:18),
15 LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-22 (SEQ ID NO:52), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-16 (SEQ ID NO:18),
20 LPIX-17 (SEQ ID NO:19), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-8 (SEQ ID NO:10), LPIX-9 (SEQ ID NO:11), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21),
25 LPIX-20 (SEQ ID NO:22), LPIX-23 (SEQ ID NO:25), LPIX-26 (SEQ ID NO:28);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-9 (SEQ ID NO:11), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-9 (SEQ ID NO:11), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-23 (SEQ ID NO:25);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:

2025.06.24 14:00:26

NO:21), LPIX-20 (SEQ ID NO:22);

5 LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID
NO:53), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-16
NO:22); and

10 LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID
NO:53), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-16
NO:22).

31. A composition comprising at least five, and no more than eight peptides, wherein at least
three, and no more than four peptides are derived from *Lol p V* and are selected from the
following group of *Lol p V* peptides: LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-11
15 (SEQ ID NO: 13), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID
NO:22), and wherein at least two, and no more than four peptides are derived from *Lol p I* and
selected from the following group of *Lol p I* peptides: LPI-16 (SEQ ID NO:46), LPI-18 (SEQ ID
NO:49), LPI-20 (SEQ ID NO:56) and LPI-23 (SEQ ID NO:53).

20 32. A composition of claim 31 wherein two peptides are derived from *Lol p I* and three
peptides are derived from *Lol p V*.

33. A composition of claim 31 wherein three peptides are derived from *Lol p I* and three
peptides are derived from *Lol p V*

25 34. A composition of claim 31 wherein three peptides are derived from *Lol p I* and four
peptides are derived from *Lol p V*.

30 35. A composition of claim 31 wherein four peptides are derived from *Lol p I* and four
peptides are derived from *Lol p V*.

36. A composition of claim 31 wherein four peptides are derived from *Lol p I* and three
peptides are derived from *Lol p V*.

SEARCHED - INDEXED - COPIED - FILED

37. Use of a composition of claims 21, 22, 23, 26, 28, 29, 30, or 31-36 in the manufacture of a medicament for use in treating sensitivity to *Lol p V* allergen or an immunologically cross-reactive allergen.

5 38. An isolated peptide of *Lol p V*, said peptide comprising at least one T cell epitope of *Lol p V*, said peptide having a positivity index of at least 60 and a mean T cell stimulation index of at least about 2.5 determined in a population of individuals sensitive to *Lol p V*.

10 39. An isolated peptide of claim 38 wherein said population of individuals is at least 15 individuals.

15 40. A portion of an isolated peptide of claim 38 wherein said portion has a positivity index of at least 60 and a mean T cell stimulation index of at least about 2.5 determined in a population of individuals sensitive to *Lol p V*.

41. An isolated peptide of claim 40 wherein said population of individuals is at least 15 individuals.

15 42. All or a portion of an isolated peptide of *Lol p I*, said peptide or portion thereof comprising at least one T cell epitope of said protein allergen, said peptide having the formula X_n-Y-Z_m , wherein Y is an amino acid sequence selected from the group consisting of: LPIX-1 (SEQ ID NO:3), LPIX-1.1 (SEQ ID NO:3), LPIX-2 (SEQ ID NO:4), LPIX-2.1 (SEQ ID NO: 4), LPIX-3 (SEQ ID NO:5), LPIX-4 (SEQ ID NO:6) LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-7 (SEQ ID NO:9), LPIX-8 (SEQ ID NO:10), LPIX-9 (SEQ ID NO:11), LPIX-10 (SEQ ID NO:12), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-13 (SEQ ID NO:15), LPIX-14 (SEQ ID NO:16), LPIX-15 (SEQ ID NO:17), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-18 (SEQ ID NO:20), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-21 (SEQ ID NO:23), LPIX-22 (SEQ ID NO:24), LPIX-23 (SEQ ID NO:25), LPIX-24 (SEQ ID NO:26), LPIX-26 (SEQ ID NO:28), 30 and LPIX-27 (SEQ ID NO:29) wherein X_n are amino acid residues contiguous to the amino terminus of Y in the amino acid sequence of said protein allergen, wherein Z_m are amino acid residues contiguous to the carboxy terminus of Y in the amino acid sequence of said protein allergen, wherein n is 0-30 and wherein m is 0-30.

43. A portion of an isolated peptide of claim 42 wherein the portion comprises at least fifteen amino acid residues.

44. An isolated nucleic acid having a nucleotide sequence coding for *Dac g I*, or the functional equivalent of said nucleotide sequence.

5 45. An isolated nucleic acid sequence of claim 44 wherein said nucleotide sequence comprises the nucleotide sequence of Fig. 16.

10 46. An expression vector comprising a nucleotide sequence coding for *Dac g I*, or the functional equivalent of said nucleotide sequence.

47. A host cell transformed to express a protein encoded by the nucleic acid of claim 44.

15 48. Isolated *Dac g I* protein produced in a host cell transformed with the nucleic acid of claim 44.

ABSTRACT

The present invention provides isolated peptides of *Lol p V*, a major protein allergen of the species *Lolium perenne*. Therapeutic peptides within the scope of the invention comprise at least one T cell epitope, or preferably at least two T cell epitopes of a protein allergen of *Lol p V*. Diagnostic peptides within the scope of the invention bind IgE. The invention also provides modified peptides having similar or enhanced therapeutic properties or other desirable properties as the corresponding, naturally-occurring allergen or portion thereof. The invention further provides nucleic acid sequences coding for peptides of the invention. Use of the therapeutic compositions comprising one or more peptides of the invention in the manufacture of medicaments for treating sensitivity to *Lol p V* or an allergen immunologically related to *Lol p V*, or for general ryegrass sensitivity in an individual, is also provided. The invention also provides nucleic acid sequence coding for *Dac g V* protein allergen as well as the amino acid sequence of *Dac g V* protein allergen.

15

08/737904

1/20

CGCTATCCCTCGTACAAACAAACGCAAGGAGCAGCAATGGCCAGTAACGGTACAGC
60
M A V Q K Y T
-25 -20
GTGGCTCTATTCTCGCCGTGGCCCTCGTGGGGGGGGGGGGGGGGCTCCTACGCCGCTGAC
120
V A L F L A V A L V A G P A A S Y A A D
-15 -10 -5 1
GCGGCTACACCCCCGGCAGCGCCACCCGGCTACTCCTGCTGCCACCCGGCTGCG
180
A G Y T P A A T P A T P A A T P A A
5 10 15 20
GCTGGAGGGAGGGGAGCGACCGAGCGAGGAAGGAGCTGCTGGAGGGACGTCAACGCTGGCTTC
240
A G G K A T T D E Q K L L E D V N A G F
25 30 35 40
AGGCAGGCCGGCCGGCTGCCAACGCCCTCCGGGGACAAGTTCAAGATCTTCGAG
300
K A V A A A N A P P A D K F K I F E
45 50 55 60
GCCGCTTCTCCGAGTCCTCCAAGGGCCTCCACCTCCGCCAACCTCCGGCCAAAGGCACCCGGC
360
A A F S E S S K G L L A T S A A K A P G
65 70 75 80
CTCATCCCCAAGGCTCGACACCGCCCTACGACGTCCGCTTACAGGCCCTACAGGCCGAGGGCGCCACC
420
L I P K L D T A Y D V A Y K A A E G A T
85 90 95 100
CCCGAGGCCAAGTACGACGCCCTCGTCACTGCCCTCACCGAAGGCGCTCCGGCTCATCGCC
480
P E A K Y D A F V T A L T E A L R V I A
105 110 115 120
GGGCCCTCGAGGGTCCACGGCCGCTCAAGGGAGGGAGGGAGGGAGGGAGGGAGGGAGGG
540
G A L E V H A V K P A T E E V P A A K I
125 130 135 140

Fig. 1

08/737904

2/20

CCACCGGGTGCAGATCGTTGACAAGATCGATGCCATTCAAGATCGCCTTCAGGCCACC 600
 P T G E L Q I V D K I D A A F K I A A T
 145 150 155 155 160
 CCGCCAAACGGCCCCACCAACGATAAGTTCACCGGTCTTCAGAGTGCTTCAACAAAG 660
 A A N A P T N D K F T V F E S A F N K
 165 170 175 175 180
 CCCTCAATGAGTGCACGGGGCGGCCTATGAGAACCTACAAGTTCATCCCTCCCTCGAG 720
 A L N E C T G G A Y E T Y K F I P S L E
 185 190 195 200
 CGCGGGTCAAGCAGGGCCTACGCCGGCCACCGTGCGCCGGCGAGGGTCAAGTACGCC 780
 A A V K Q A Y A T V A A P E V K Y A
 205 210 215 220
 TCTTTGAGGGCGGCTGACCAAGGCCATCACCGGCCATGACCCAGGCACAGAAGGCCGGC 840
 V F E A L T K A I T A M T Q A Q K A G
 225 230 235 240
 AACCCGCTGCCGGCTGCCACAGGGCCAACCGGTTGCCACCGGGCCAACCGGCC 900
 K P A A A T G A A T V A T G A A T A
 245 250 255 260
 CGCCGGGTGCTGCCACCGCCGCTGCTGGCTACAAAGCCTGATCAGCTTGCTTAATAT 960
 A A G A A T A A G G Y K A *
 265 270 275
 CTACTGAACGTTATGTTGATGATGCCATGATGCCGGGGGGGGGAGTGGTTTGATAATTAAATC 1020
 TCGTTTTCGTTTCATGCCAGGGCGATCGAGGGGCTTGCATGCTTGTAAATTCAATA 1080
 TTTTCAATTCTTTGAAATCTGTAATCCCCATGACAAGTAGTGGATCAAGTGGCAT 1140
 TATCACCCGGTGTGATGCCAGTTAACGATGGGGAGTTATCANAAGAATTATTAAAAAA 1200
 AAAAAAAA
 1229

Fig. 1 cont.

3/20

LIX-1 ADAGYTXAAATXATXAATX
LIX-1.1 ADAGYTPAAAATPATPAATP
LIX-2 ATXATXAATXAAAGGKATT
LIX-2.1 ATPATPAATPAAAGGKATT
LIX-3 AAAGGKATTDEQKLLEDVNA
LIX-4 EQKLLEDVNAGFKAAVAAAA
LIX-5 GFKAAVAAAANAPPADKF
LIX-6 NAPPADKF
LIX-7 FEAAFSESSKG
LIX-8 LATSAAKAPGLIPKLD
LIX-9 PGLIPKLD
LIX-10 YDVAYKAAEGATPEAKYD
LIX-11 ATPEAKYD
LIX-12 AFVTALTEALRV
LIX-13 VTLTEALRVIAGALEVHAV
LIX-14 IAGALEVHAVKP
LIX-15 ATPEEVPAAKIPTGELQIV
LIX-16 KP
LIX-17 IKTGELQIVDK
LIX-18 KIDA
LIX-19 AAFKIAATAANAA
LIX-20 PTD
LIX-21 NK
LIX-22 FESAFN
LIX-23 KALNECTGGAYETYKF
LIX-24 IPS
LIX-25 LEAAVKQAYAATVAA
LIX-26 APEVK
LIX-27 YAVFEAALT
LIX-28 KAITAMTQAQK
LIX-29 AGK
LIX-30 PAAAATGAATVATGAA
LIX-31 GAATVATGAATAA
LIX-32 AGAATAA
LIX-33 AGGYKA

X REPRESENTS HYDROXYPROLINE RESIDUE

Fig. 2

8/08/73 904

4/20

PEPTIDE NAME	PEPTIDE SEQUENCE
LPI-1	IAKVPPGPNIATAEYGDKWLD
LPI-1.1	IAKVVXPGXNITAEYGDKWLD
LPI-2	TAEYGDKWLD ^A AKSTWY ^B GKPT
LPI-3	AKSTWY ^B GKPTGAGPKDNGGA
LPI-4	GAGPKDNGGACGYKNVDKAP
LPI-4.1	GAGPKDNGGACGYKDVKAP
LPI-5	CGYKDVKAPFNGMTGCGNT
LPI-6	FNGMTGCGNTP ^A IFKDGRGCG
LPI-7	PIFKDGRGCGSCFEIKCTKP
LPI-8	SCFEIKCTKPESCSGEAVTV
LPI-9	ESCSGEAVTVTITDDNEEPI
LPI-10	TITDDNEEPIAPYHFDLSGH
LPI-11	APYHFDLSGHAFGSMADDGE
LPI-11.1	APYHFDLSGHAFGSM ^A KKGE
LPI-12	AFGSMADDGEEQKLRSAGEL
LPI-12.1	AFGSM ^A KKGEEQKLRSAGEL
LPI-13	EQKLRSAGELELQFRRVKCK
LPI-14	ELQFRRVKCK ^A YPDDTKPTFH
LPI-15	YPDDTKPTFHVEKASNPNYL
LPI-16	VEKASNPNYLAILVKYVDGD
LPI-16.1	VEKG ^A SNPNYLAILVKYVDGD
LPI-17	AILVKYVDGDGVVAVDIKE
LPI-18	GDVVAVDIKEKGKDKWIELK
LPI-19	KGKDKWIELKESWGAVWRID
LPI-20	ESWGAVWRIDTPDKLTGPFT
LPI-21	TPDKLTGPFTVRYTTEGGTK
LPI-22	VRYTTEGGTKSEVEDVIPEG
LPI-23	SEVEDVIPEGWKADTSYSAK

Fig. 3

08/737904

5/20




Fig. 4

08/737904

6/20




Fig. 5

08/737904

7/20




Fig. 6

08/737904

8/20




Fig. 7

08/737904

9/20




Fig. 8

08/737904

10/20



Fig. 9

08/737904

11/20




Fig. 10

08/737904

12/20




Fig. 11

08/737904

13/20




Fig. 12

08/737904

14/20




Fig. 13A

08/737904

15/20




Fig. 13B

08/737904

16/20




Fig. 14

08/737904

17/20




Fig. 15

08/737904

18/20

GAATTGGGATACACGGTGGCGCTGTTCCCTGGCCGTGGCTCGTGTCTCGGGCCGGCCAAACCAAGGCAATGGCA 58
M A
-24
TGCGAGTACACGGTGGCGCTGTTCCCTGGCCGTGGCTCGTGTCTCGGGCCGGCCAAACCAAGGCAATGGCA 118
V Q Q Y T V A L F L A V A S C R A R A S
-20
CACGCCGGGACTACGCCGGCTACGCCGGCACTCCCCGCCACCTACCCGGCTAACCCCGGCC 178
Y A A D A G Y A P A T P A T P A T P A A
10
CAGGGCGAGCGGTGCCAGCAGGGAAAGGGCGGGGACCGAGGAGCAGAAGCTGATCGAGAAG 238
P G A A V P A G K A A T E E Q K L I E K
20
ATCAACGGGCTTCAAGGGCCGGCGCCGGCGGGCGGGCGGGCTCCGCCAGGGCAGCAAG 298
I N A G F K A V A A A G V P P A D K
40
ACAAGACGTTCTGGCAAACCTTCGGCAAAGGCCCTGGCTCAACAAAGGCCCTTCCTGGGGGACCTC 358
Y K T F V E T F G K A S N K A F L G D L
60
CGACCAACTACGCCGATGTCAACTCCAGGGCCAGCTCACCTCGAAAGTACGACGCC 418
P T N Y A D V N S R A Q L T S K L D A A
80
ACAAGCTCGCCCTACGACGCCGGCCAGGGCCACCCCCCGAGGCCAAGTACGACGCC 478
Y K L A Y D A A Q G A T P E A K Y D A Y
100
110

Fig. 16

19/20

TCGCCACCCCTCAGCGAGGGCCTCCGCATCATGCCGGCACCCCTCGAGGTCCACGCCGTC 538
 V A T L S E A L R I I A G T L E V H A V
 120
 AGCCCGCTGCCGAGGGTCAAGGCCTATCCCCGGAGAGCTGCAGATCGTCGACAAG 598
 K P A A E E V K P I P A G E L Q I V D K
 140
 TTGACGTCGCGCTTCAGAACTGCGGCCAACGCCAACGGACAAAG 658
 I D V A F R T A A T A N A A P T N D K
 160
 TCACCGTATTGAGACCACCTTAACAAAGGCCATCAAGGAGAGCACGGGGCACCTAC 718
 F T V F E T T F N K A I K E S T G G T Y
 180
 AGAGCTACAAAGTTCATCCCACCCCTTGAGGCCCGTTAACGCAGGCCCTACGCCACC 778
 E S Y K F I P T L E A A V K Q A Y A A T
 200
 TCGCATCCGGAGGGTCAAGTACGCCGTCTTGTAGACCCGGCTGAAAAGGGGGTC 838
 V A S A P E V K Y A V F E T A L K K A V
 220
 CCGCCATGTCCGGGCCAGAAGGAAGCCAAAGCCGCCACCCGGACCCCAAC 898
 T A M S E A Q K E A K P A T P T P T
 240
 250

Fig. 16 cont.

08/737904

20/20

CAACTGCCGGCGGTGGCCACCAACGCCGGCCGGTGGCTGGCTGGTGGCTACAAA 958
A T A A V A T N A A P V A A G G Y K
260
TCTGATCAACTCGCTAGCAATAACACATCCCATGCACATATAAGGCTGTGTATGTA 1018
T *
GTGCATGCCATGCCGGCGCAAGTTGCTCATAAATTAAATTCTGGTTTCGTTG 1078
TTGCATCCACGAGCGACCGAGGCCGTGGATAGTCGCATGTGTATGTAATTTTCTGAG 1138
AATGTGTATGTAATAATTGAGTACTAAAAAA 1181

Fig. 16 cont.

Attorney's
Docket
Number IMI-040CP3

Declaration, Petition and Power of Attorney For Patent Application

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

T CELL EPITOPES OF RYEGRASS POLLEN ALLERGEN

the specification of which

(check one)

_ is attached hereto.

X was filed on August 5, 1994 as

PCT Application Serial No. PCT/US94/09024

and was amended on _____
(if applicable)

I do not know and do not believe that the subject matter of this application was ever known or used in the United States before my invention thereof or patented or described in any printed publication in any country before my invention thereof or more than one year prior to the date of this application, and that said subject matter has not been patented or made the subject of an issued inventor's certificate in any country foreign to the United States on an application filed by me or my legal representatives or assigns more than twelve months prior to the date of this application; that I acknowledge my duty to disclose information of which I am aware which is material to the examination of this application, that no application for patent or inventor's certificate on the subject matter of this application has been filed by me or my representatives or assigns in any country foreign to the United States, except those identified below, and that I have reviewed and understand the contents of the specification, including the claims as amended by any amendment referred to herein.

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

PRIORITY CLAIM

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

Check one:

no such applications have been filed.

such applications have been filed as follows

EARLIEST FOREIGN APPLICATION(S), IF ANY FILED WITHIN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

Country	Application Number	Date of Filing (month,day,year)	Priority Claimed Under 35 USC 119
			<input type="checkbox"/> Yes <input type="checkbox"/> No _____
			<input type="checkbox"/> Yes <input type="checkbox"/> No _____
			<input type="checkbox"/> Yes <input type="checkbox"/> No _____
			<input type="checkbox"/> Yes <input type="checkbox"/> No _____
			<input type="checkbox"/> Yes <input type="checkbox"/> No _____

ALL FOREIGN APPLICATION(S), IF ANY FILED MORE THAN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

CLAIM FOR BENEFIT OF U.S. PROVISIONAL APPLICATION(S)

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

2

CLAIM FOR BENEFIT OF EARLIER U.S./PCT APPLICATION(S)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application. As to subject matter of this application which is common to my earlier United States application, if any, described below, I do not believe that the same was ever known or used in the United States before my invention thereof or patented or described in any printed publication in any country before my invention thereof or more than one year prior to said earlier application, or in public use or on sale in the United States more than one year prior to said earlier application, that the said common subject matter has not been patented or made the subject of an inventor's certificate issued before the date of said earlier application in any country foreign to the United States on an application, filed by me or my legal representatives or assigns more than twelve months prior to said application and that no application for patent or inventor's certificate on said subject matter has been filed by me or my representatives or assigns in any country foreign to the United States except those identified herein.

<u>08/106,016</u> (Application Serial No.)	<u>August 13, 1993</u> (Filing Date)	<u>Pending</u> (Status) (patented,pending,aband.)
---	---	---

<u>PCT/US94/09024</u> (Application Serial No.)	<u>August 5, 1994</u> (Filing Date)	<u>Pending</u> (Status) (patented,pending,aband.)
---	--	---

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorneys and/or agents to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

John A. Lahive, Jr.	Reg. No. <u>19,788</u>	Jeremiah Lynch	Reg. No. <u>17,425</u>
W. Hugo Liepmann	Reg. No. <u>20,407</u>	Amy E. Mandragouras	Reg. No. <u>36,207</u>
James E. Cockfield	Reg. No. <u>19,162</u>	Elizabeth A. Hanley	Reg. No. <u>33,505</u>
Thomas V. Smurzynski	Reg. No. <u>24,798</u>	Anthony A. Laurentano	Reg. No. <u>38,220</u>
Ralph A. Loren	Reg. No. <u>29,325</u>	Jane E. Remillard	Reg. No. <u>38,872</u>
Thomas J. Engellenner	Reg. No. <u>28,711</u>	Mark A. Kurisko	Reg. No. <u>38,944</u>
Giulio A. DeConti, Jr.	Reg. No. <u>31,503</u>	Beth E. Arnold	Reg. No. <u>35,430</u>
Ann Lamport Hammitt	Reg. No. <u>34,858</u>	Jean M. Silveri	Reg. No. <u>39,030</u>
Paul Louis Myers	Reg. No. <u>35,965</u>	Matthew P. Vincent	Reg. No. <u>36,709</u>
Michael I. Falkoff	Reg. No. <u>30,833</u>	Lawrence E. Monks	Reg. No. <u>34,224</u>
John V. Bianco	Reg. No. <u>36,748</u>		

21

Send Correspondence to:


Lahive & Cockfield, 60 State Street, Boston, MA 02109

Direct Telephone Calls to: (name and telephone number)

Giulio A. DeConti, Jr., (617) 227-7400

Wherefore I petition that letters patent be granted to me for the invention or discovery described and claimed in the attached specification and claims, and hereby subscribe my name to said specification and claims and to the foregoing declaration, power of attorney, and this petition.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor <u>Irwin J. Griffith</u>	Date
Inventor's signature 	<u>11 Sept 96</u>
Residence 401 Rooney Crescent, <u>Edmonton, AB T6R 1C5, Canada</u> <u>CA</u>	
Citizenship United States of America	
Post Office Address (if different) Same as above	

Full name of second inventor, if any <u>Mei-Chang Kuo</u> <u>Q-00</u>	
Inventor's signature	Date
Residence 1380 Oak Creed Drive, Apt. #206, Palo Alto, CA 94304 <u>CA</u>	
Citizenship United States of America	
Post Office Address (if different) Same as above	

Full name of third inventor, if any <u>Mohammad Luqman</u> <u>3-00</u>	
Inventor's signature	Date
Residence 13 Carriage Drive, Acton, MA 01720 <u>MA</u>	
Citizenship India	
Post Office Address (if different) Same as above	

Attorney's
Docket
Number IMI-040CP3

Declaration, Petition and Power of Attorney For Patent Application

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

T CELL EPITOPES OF RYEGRASS POLLEN ALLERGEN

the specification of which

(check one)

_ is attached hereto.

X was filed on August 5, 1994 as

PCT Application Serial No. PCT/US94/09024

and was amended on _____
(if applicable)

I do not know and do not believe that the subject matter of this application was ever known or used in the United States before my invention thereof or patented or described in any printed publication in any country before my invention thereof or more than one year prior to the date of this application, and that said subject matter has not been patented or made the subject of an issued inventor's certificate in any country foreign to the United States on an application filed by me or my legal representatives or assigns more than twelve months prior to the date of this application; that I acknowledge my duty to disclose information of which I am aware which is material to the examination of this application, that no application for patent or inventor's certificate on the subject matter of this application has been filed by me or my representatives or assigns in any country foreign to the United States, except those identified below, and that I have reviewed and understand the contents of the specification, including the claims as amended by any amendment referred to herein.

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

PRIORITY CLAIM

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

Check one:

no such applications have been filed.

such applications have been filed as follows

EARLIEST FOREIGN APPLICATION(S), IF ANY FILED WITHIN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

Country	Application Number	Date of Filing (month,day,year)	Priority Claimed Under 35 USC 119
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No

ALL FOREIGN APPLICATION(S), IF ANY FILED MORE THAN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

CLAIM FOR BENEFIT OF U.S. PROVISIONAL APPLICATION(S)

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

CLAIM FOR BENEFIT OF EARLIER U.S./PCT APPLICATION(S)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application. As to subject matter of this application which is common to my earlier United States application, if any, described below, I do not believe that the same was ever known or used in the United States before my invention thereof or patented or described in any printed publication in any country before my invention thereof or more than one year prior to said earlier application, or in public use or on sale in the United States more than one year prior to said earlier application, that the said common subject matter has not been patented or made the subject of an inventor's certificate issued before the date of said earlier application in any country foreign to the United States on an application, filed by me or my legal representatives or assigns more than twelve months prior to said application and that no application for patent or inventor's certificate on said subject matter has been filed by me or my representatives or assigns in any country foreign to the United States except those identified herein.

<u>08/106,016</u> (Application Serial No.)	<u>August 13, 1993</u> (Filing Date)	<u>Pending</u> (Status) (patented,pending,aband.)
---	---	---

<u>PCT/US94/09024</u> (Application Serial No.)	<u>August 5, 1994</u> (Filing Date)	<u>Pending</u> (Status) (patented,pending,aband.)
---	--	---

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorneys and/or agents to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

John A. Lahive, Jr.	Reg. No. 19,788	Jeremiah Lynch	Reg. No. 17,425
W. Hugo Liepmann	Reg. No. 20,407	Amy E. Mandragouras	Reg. No. 36,207
James E. Cockfield	Reg. No. 19,162	Elizabeth A. Hanley	Reg. No. 33,505
Thomas V. Smurzynski	Reg. No. 24,798	Anthony A. Laurentano	Reg. No. 38,220
Ralph A. Loren	Reg. No. 29,325	Jane E. Remillard	Reg. No. 38,872
Thomas J. Engellenner	Reg. No. 28,711	Mark A. Kurisko	Reg. No. 38,944
Giulio A. DeConti, Jr.	Reg. No. 31,503	Beth E. Arnold	Reg. No. 35,430
Ann Lampert Hammitt	Reg. No. 34,858	Jean M. Silveri	Reg. No. 39,030
Paul Louis Myers	Reg. No. 35,965	Matthew P. Vincent	Reg. No. 36,709
Michael I. Falkoff	Reg. No. 30,833	Lawrence E. Monks	Reg. No. 34,224
John V. Bianco	Reg. No. 36,748		

Send Correspondence to:

Lahive & Cockfield, 60 State Street, Boston, MA 02109

Direct Telephone Calls to: (name and telephone number)

Giulio A. DeConti, Jr., (617) 227-7400

Wherefore I petition that letters patent be granted to me for the invention or discovery described and claimed in the attached specification and claims, and hereby subscribe my name to said specification and claims and to the foregoing declaration, power of attorney, and this petition.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor Irwin J. Griffith	
Inventor's signature	Date
Residence 401 Rooney Crescent, Edmonton, AB T6R 1C5, Canada	
Citizenship United States of America	
Post Office Address (if different) Same as above	

Full name of second inventor, if any Mei-Chang Kuo	
Inventor's signature <i>Mei-chang Kuo</i>	Date 9/24/96
Residence 1823 Middlefield Road, Palo Alto, CA 94301 1380 Oak Creed Drive, Apt. #206, Palo Alto, CA 94304	
Citizenship United States of America	
Post Office Address (if different) Same as above	

Full name of third inventor, if any Mohammad Luqman	
Inventor's signature	Date
Residence 13 Carriage Drive, Acton, MA 01720	
Citizenship India	
Post Office Address (if different) Same as above	

Attorney's
Docket
Number IMI-040CP3

Declaration, Petition and Power of Attorney For Patent Application

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

T CELL EPITOPES OF RYEGRASS POLLEN ALLERGEN

the specification of which

(check one)

 is attached hereto.

X was filed on August 5, 1994 as

PCT Application Serial No. PCT/US94/09024

and was amended on _____
(if applicable)

I do not know and do not believe that the subject matter of this application was ever known or used in the United States before my invention thereof or patented or described in any printed publication in any country before my invention thereof or more than one year prior to the date of this application, and that said subject matter has not been patented or made the subject of an issued inventor's certificate in any country foreign to the United States on an application filed by me or my legal representatives or assigns more than twelve months prior to the date of this application; that I acknowledge my duty to disclose information of which I am aware which is material to the examination of this application, that no application for patent or inventor's certificate on the subject matter of this application has been filed by me or my representatives or assigns in any country foreign to the United States, except those identified below, and that I have reviewed and understand the contents of the specification, including the claims as amended by any amendment referred to herein.

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

PRIORITY CLAIM

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

Check one:

no such applications have been filed.

such applications have been filed as follows

EARLIEST FOREIGN APPLICATION(S), IF ANY FILED WITHIN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

Country	Application Number	Date of Filing (month,day,year)	Priority Claimed Under 35 USC 119
			- Yes No -
			- Yes No -
			- Yes No -
			- Yes No -
			- Yes No -

ALL FOREIGN APPLICATION(S), IF ANY FILED MORE THAN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

CLAIM FOR BENEFIT OF U.S. PROVISIONAL APPLICATION(S)

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

CLAIM FOR BENEFIT OF EARLIER U.S./PCT APPLICATION(S)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application. As to subject matter of this application which is common to my earlier United States application, if any, described below, I do not believe that the same was ever known or used in the United States before my invention thereof or patented or described in any printed publication in any country before my invention thereof or more than one year prior to said earlier application, or in public use or on sale in the United States more than one year prior to said earlier application, that the said common subject matter has not been patented or made the subject of an inventor's certificate issued before the date of said earlier application in any country foreign to the United States on an application, filed by me or my legal representatives or assigns more than twelve months prior to said application and that no application for patent or inventor's certificate on said subject matter has been filed by me or my representatives or assigns in any country foreign to the United States except those identified herein.

<u>08/106,016</u> (Application Serial No.)	<u>August 13, 1993</u> (Filing Date)	<u>Pending</u> (Status) (patented,pending,aband.)
---	---	---

<u>PCT/US94/09024</u> (Application Serial No.)	<u>August 5, 1994</u> (Filing Date)	<u>Pending</u> (Status) (patented,pending,aband.)
---	--	---

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorneys and/or agents to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

John A. Lahive, Jr.	Reg. No. 19,788	Jeremiah Lynch	Reg. No. 17,425
W. Hugo Liepmann	Reg. No. 20,407	Amy E. Mandragouras	Reg. No. 36,207
James E. Cockfield	Reg. No. 19,162	Elizabeth A. Hanley	Reg. No. 33,505
Thomas V. Smurzynski	Reg. No. 24,798	Anthony A. Laurentano	Reg. No. 38,220
Ralph A. Loren	Reg. No. 29,325	Jane E. Remillard	Reg. No. 38,872
Thomas J. Engellenner	Reg. No. 28,711	Mark A. Kurisko	Reg. No. 38,944
Giulio A. DeConti, Jr.	Reg. No. 31,503	Beth E. Arnold	Reg. No. 35,430
Ann Lampert Hammitt	Reg. No. 34,858	Jean M. Silveri	Reg. No. 39,030
Paul Louis Myers	Reg. No. 35,965	Matthew P. Vincent	Reg. No. 36,709
Michael I. Falkoff	Reg. No. 30,833	Lawrence E. Monks	Reg. No. 34,224
John V. Bianco	Reg. No. 36,748		

Send Correspondence to:

Lahive & Cockfield, 60 State Street, Boston, MA 02109

Direct Telephone Calls to: (name and telephone number)

Giulio A. DeConti, Jr., (617) 227-7400

Wherefore I petition that letters patent be granted to me for the invention or discovery described and claimed in the attached specification and claims, and hereby subscribe my name to said specification and claims and to the foregoing declaration, power of attorney, and this petition.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor Irwin J. Griffith	Date
Inventor's signature	
Residence 401 Rooney Crescent, Edmonton, AB T6R 1C5, Canada	
Citizenship United States of America	
Post Office Address (if different) Same as above	

Full name of second inventor, if any Mei-Chang Kuo	
Inventor's signature	Date
Residence 1380 Oak Creed Drive, Apt. #206, Palo Alto, CA 94304	
Citizenship United States of America	
Post Office Address (if different) Same as above	

Full name of third inventor, if any Mohammad Luqman	
Inventor's signature	Date
Residence 13 Carriage Drive, Acton, MA 01720	
Citizenship India	
Post Office Address (if different) Same as above	